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Abnormal Smear: Smears showing cervical cell abnormalities called  
  dyskaryosis, but not benign changes such as infection or hormonal 
  influences (Ni Riain et al, 2003, p. 66). 
 
Biopsy: Removal of a sample of tissue from the body, for examination 
under a microscope (Ni Riain et al, 2003, p. 66).  
 
Cervical Intraepithelial Neoplasia (CIN): Cervical Intraepithelial Neoplasia is  
  not cancer. It is a histological (examination of a tissue biopsy) 
  diagnosis. It describes varying degrees of abnormality of the cells  
  within and confined to the epithelium (cervical lining or ‘skin’).  
  There are three grades of CIN: I, II, III (Ni Riain et al, 2003, p. 66). 
 
Cervical Cancer: Cancer of the cervix. Cancer cells have spread beyond the 
  natural basement membrane boundary of the cervical skin. (Ni  
  Riain et al, 2003, p. 66). 
 
Cervical Cytology: A microscope examination of cells scraped from the surface  
  of the cervix, for signs of abnormality (Ni Riain et al, 2003, p.66). 
 
Cervical Smear Test: A screening test where a sample of the surface cells are  
  taken from the skin of the cervix or vagina/vault, preserved  
  immediately and sent to the laboratory for microscope examination 
  (Ni Riain et al, 2003, p. 66). 
 
Cohort: A generational group (Layte et al, 2006, p. xix) 
 
Colposcopy:  A low power magnification, light illuminated examination of the 
cervix and vagina looking for abnormalities of the tissue, carried out 
in a hospital with specialised facilities (Ni Riain et al, 2003, p. 66).   
 
Cone Biopsy: A surgical removal of a cone-shaped section of the cervix to  
  remove abnormal cells. The procedure is diagnostic but may be  
  curative as well (Ni Riain et al, 2003, p.66). 
 
Dyskaryosis: Term used in cytology to describe nuclear abnormalities in cervical  
  cells. Dyskaryotic cells are classified as mild, moderate and severe  
  and correlate with CIN I, CIN II and CIN III (Ni Riain et al, 2003,  
  p. 66). 
 
HPV:   Human Papillomavirus is a group of wart viruses, of which a high  
  proportion are sexually transmitted (Ni Riain et al, 2003, p. 67). 
 
Hysterectomy: The surgical removal of the uterus (womb) – called total if it  
  includes the cervix or subtotal / partial if the cervix is not entirely  
  removed (Ni Riain et al, 2003, p. 67). 
 viii
Inadequate Smear: A smear that cannot be safely read and reported by the  
  laboratory. Causes include obscuring by blood or exudates,  
  insufficient cells, destruction of cells due to air-drying or   
  mishandling, broken slide (Ni Riain et al, 2003, p. 69). 
 
LLETZ:  Large Loop Excision of the Transformation Zone is a diagnostic  
  and/or  treatment method to remove the cervical areas of   
  abnormality or concern (Ni Riain et al, 2003, p. 67).   
 
Mortality:  The number of deaths from a specified disease during a defined  
  period of time in a given population (Ni Riain et al, 2003, p. 67). 
 
Normal Smear: A smear result which is reported to be within normal limits (Ni  
  Riain et al, 2003, p. 68). 
 
Opportunistic Smear/Screening: A smear done when the opportunity presents,  
  irrespective of the woman's ICSP eligibility or screening   
  requirements: self referral (Ni Riain et al, 2003, p.68). 
 
Population-based Screening Programme: An organized approach of managing  
  a population of people to be screened to determine the likelihood  
  of the disease, or not, that is being screened for (Ni Riain et al,  
  2003, p. 68). 
 
Prevalence (rate): May refer to have precancerous cervical abnormality or 
   cancer. It is the total number of women who have a cervical  
  precancerous lesion or cancer at a particular time (or during a  
  particular period) divided by the population at risk of having a  
  cervical precancerous lesion or cancer at this point in time or  
  midway through the period (Ni Riain et al, 2003, p. 68). 
 
Radical hysterectomy: Removal of the uterus, cervix, cuff of the vagina,   
  parametrial tissues and pelvic lymph nodes (Ni Riain et al, 2003, p. 
  10).  
 
Radical radiotherapy: External beam radiation or brachytherapy where  
  radioactive isotopes are placed within or adjacent to the tumour (Ni 
  Riain et al, 2003, p. 10).  
 
Transformation Zone: The region of the cervix where the columnar cells of the  
  inner cervix have or are changing to outer squamous cells. The 
  process of change is call metaplasia. It is the area most at risk of  






List of Tables 
Table               Page 
Table 1: Participants ages’…………………………………..…….………26 
Table 2:  Participants’ mean age at first sexual intercourse and mean  
  number of sexual partners ….……………………………………33 
Table 3:  Participants’ inclination to ask about their sexual partners sexual  
  history ...………………………………………………………….34 
Table 4:  Participants’ current (or last) sexual partner’s mean number of  
previous sexual partners ………………...……………………….34 
Table 5:           Participants’ incidence of STIs and smoking …………………....35 
Table 6: Participants’ mean incidence of smoking per week ……………..35 
Table 7:  Inter-correlation of sexual behaviour risk-factors ...……………..37 
Table 8:  Summary of results for the presence of the risk-factors …..…….38 
Table 9:  Mean age at, and number and interval of cervical smear tests .....40 
Table 10:  Participants’ age at sexual debut and initiation of cervical   
  screening ………………………………………………………...42 
Table 11:  Attendance for cervical screening relative to the presence of the  
  risk-factors …...…………………………………………………..45 
Table 12:  Distribution of participants known cervical smear test results ….46 
Table 13:  Cervical screening results, relative to the presence of the   
  risk-factors …...…………………………………………………..50 
Table 14:  Knowledge of the purpose of a cervical smear test ...……………52 
Table 15:         Knowledge of the meaning of a normal cervical smear test 
 result ……………………………………………………………..52 
Table 16:  Knowledge of the risk-factors for contracting HPV ..…………...53 
Table 17:  Personal barriers to cervical screening ...………………………...56 







List of Figures 
Figures                              Page 
Figure 1: Distribution of participants’ ages………………..……….………26 
Figure 2:  Distribution of participants’ ages at first sexual intercourse .....…33 
Figure 3:  Participants’ lifetime number of sexual partners …..……………34 
Figure 4:  Participants’ current (or last) sexual partner’s number of previous  
  sexual partners ...…………………………………………………35 
Figure 5:  Distribution and length of oral contraceptive pill use ...…………36 
Figure 6:  Participants’ mean number of sexual partners and incidence of  
  STIs ..…………………………………………………………….37 
Figure 7:  Participants’ mean age at sexual debut and incidence of STIs .....38 
Figure 8:  Participants current age and cervical screening attendance ..……39 
Figure 9:  Participants’ age at first cervical smear test ...…………………...40 
Figure 10:  Cost of, and attendance for, cervical screening ...………………..40 
Figure 11:  Participants’ cervical screening attendance and age at sexual  
debut ……………………………………………………………..41 
Figure 12:  Participants’ cervical smear test attendance and number of   
  sexual partners ………………………………………...…………42 
Figure 13:  Participants’ cervical smear test attendance by their partner’s  
  number of previous sexual partners ..…………………...……….43 
Figure 14:  Participants’ cervical smear test attendance and their incidence  
  of sexually transmitted infections …..…………………………...43 
Figure 15:  Participants’ cervical smear test attendance and their incidence  
  of smoking ……………..………………………………………...44 
Figure 16:  Participants’ cervical smear test attendance in relation to increasing 
  duration of oral contraceptive pill use ...…………………………44 
Figure 17:  Management and treatment of cervical abnormalities ..…………46 
Figure 18:  Participants’ age at sexual debut and their cervical screening  
  results ……………………………………………………………47 
Figure 19:  Participants’ lifetime number of sexual partners and their cervical 
  screening results ………………………………………………..47 
 xi
Figure 20:  Participants’ cervical screening results and their partner’s number  
  of sexual partners …..……………………………………………48 
Figure 21:  Participants’ cervical screening results and their incidence of  
sexually transmitted infections …………………...………….…..48 
Figure 22:  Participants’ cervical screening results and their incidence of  
  smoking …..……………………………………………………...49 
Figure 23:  Participants’ cervical screening results and their mean number  
of cigarettes smoked per week ….……………..…………...……49 
Figure 24:  Participants’ cervical screening results and length of oral   
contraceptive pill use …...………………….…………………….50 
Figure 25:  Participants’ perceived sufficient knowledge of cervical cancer,  
cervical screening and HPV ..……………………………………51 
Figure 26: Knowledge of participants who had attended for cervical  
screening……………………..…………………………………..52  
Figure 27:  Information included in sex education …………………………..54 





















This study had three aims: to determine the prevalence of the risk-factors for 
contracting HPV (the Human Papillomavirus) and developing cervical cancer 
among young women; to establish if there are any links between the presence of 
these risk-factors, attendance for cervical screening and abnormal cervical 
screening results; and to ascertain the key barriers to the prevention of cervical 
cancer.  The risk-factors were identified from literature as being sexually active at 
a young age, having increasing numbers of sexual partners for females and their 
partners, having had a sexually transmitted infection/disease (STI), smoking and 
long-term use of the oral contraceptive pill.  The research was conducted through 
a quantitative, self-completion internet survey, completed by 242 women aged 18-
24 attending a third-level institute and analysed using SPSS (the Statistical 
Package for Social Sciences).  The findings showed that the prevalence of the 
sexual behaviour risk-factors tended to occur concurrently; being sexually active 
before age 17 was linked to increasing numbers of sexual partners and the 
occurrence of STIs.  The findings also showed that approximately one-quarter of 
participants had attended for cervical screening, of which, over one-third reported 
abnormal results.  Additionally, the findings demonstrated that the presence of the 
abovementioned sexual behaviour risk-factors tended to increase the likelihood of 
cervical screening attendance and the reception of an abnormal result.  The key 
barriers to the prevention of cervical cancer were identified as a lack of 
knowledge about the primary and secondary prevention of cervical cancer: HPV 
and cervical screening respectively.  The present study recommended that firstly, 
as the prevalence of the risk-factors appear to be increasing, cervical screening 
should be initiated from age 20 onwards, on the basis of the presence of the risk-
factors, rather than being age-standardised at 25, and secondly, greater education 
and communication on the primary and secondary prevention of cervical cancer 




1.1 Introduction  
This paper examines the prevalence of the risk-factors for developing cervical 
cancer among young women1 attending a third-level institute.  Chapter One 
begins by illustrating the aims of the study and then explains the rationale for the 
research and provides an outline of the study.  
 
1.2 Aims of the study 
This study addresses the following three research questions: 
1. What is the prevalence of the risk-factors for contracting HPV (the Human 
Papillomavirus) and developing cervical cancer among young women 
attending a third-level institute? 
2. Are there any links between the presence of these risk-factors, attendance 
for cervical screening and the young women’s abnormal cervical screening 
results?  
3. What are the key barriers to the prevention of cervical cancer among these 
young women? 
 
In addressing these questions, the association between HPV, a sexually 
transmitted infection (STI), and cervical cancer is examined and the main risk-
factors for contracting HPV and developing cervical cancer are identified from 
literature (International Agency for Research on Cancer, 2003, 2005).   
 
Additionally, this study endeavours to answer these questions through the use of a 
quantitative, semi-standardised, self-completion questionnaire designed by the 
researcher (see Appendix A).  These questionnaires were voluntarily completed 
via the internet, by 242 sexually active young women attending a third level 
institute.  
 
1.3 Rationale of the Study  
This study was undertaken as a result of discovering that young women have the 
third highest age-specific incidence rates of preinvasive cervical cancer in Ireland 
                                                 
1 Throughout this paper, the terms ‘young women’, ‘young men’ or ‘young people’, refers to the 
respective group between the ages of 18 and 24 inclusive. 
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(see Appendix B) (National Cancer Registry Ireland, 2006) and are also the third 
highest age group in attendance for colposcopy (a microscopic examination of the 
cervix) (Irish Cervical Screening Programme, 2004b).  Yet, despite these statistics, 
there are great inconsistencies regarding the age at which age a young women 
should first attend for a cervical smear test; some doctors advise that within three 
years of first sexual intercourse a women should attend for cervical screening, 
while other doctors and the Irish Cervical Screening Programme (ICSP) advocate 
that screening women under the age of 25 is unnecessary, as invasive cervical 
cancer seldom occurs in this age group (Ni Riain, et al, 2003; CervicalCheck, 
2008).  Furthermore, ‘CervicalCheck- The National Cervical Screening 
Programme’ which has incorporated the ICSP and was launched in September 
2008, is firstly, excluding all women aged under 25 from partaking in its cervical 
screening programme and secondly, is discouraging women under 25 from 
attending for opportunistic (self-referral) cervical screening, regardless of the 
presence of the risk-factors for developing cervical cancer (CervicalCheck, 2008; 
Martin et al, 2007).   
 
Interest in this study was also garnered because of the recent availability of a 
vaccine against HPV: will it result in young women forgoing cervical screening in 
the belief that HPV-vaccination provides total protection against cervical cancer, 
even though other factors work in tandem with HPV to contribute to one’s risk of 
cervical cancer (International Agency for Research on Cancer, 2005).  
 
1.4 Outline of the Study 
Chapter One gives a brief outline of the research study, the aims of the research 
and the rationale for undertaking this study. 
 
Chapter Two presents the literature review.  Firstly, the theoretical framework on 
cervical screening and cervical cancer prevention in Ireland is examined.  Next, 
the association between HPV and cervical cancer is explored, as are the risk-
factors for contracting HPV and developing cervical cancer.  Afterwards, the 
prevalence of these risk-factors among young women is briefly considered in the 
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Irish context and then the key barriers to the prevention of cervical cancer are 
investigated, including the impact that knowledge, or lack thereof, has on cervical 
cancer prevention.  The initiation of cervical screening in various countries is then 
contemplated, drawing on international cervical screening guidelines, and lastly a 
summary is drawn.  
 
Chapter Three outlines the research methodology of the present study and 
discusses the sampling framework and selection of participants.  The chosen data 
collection method is then justified and the research instrument, the ethics of the 
study and the analysis of the data are considered.  
 
Chapter Four presents the research findings from the present study under several 
headings, including: the prevalence of the HPV and cervical cancer risk-factors, 
participants’ cervical smear test attendance and results in relation to the risk-
factors, and participants’ key barriers to cervical cancer prevention, including 
their knowledge of cervical cancer prevention.   
 
Chapter Five discusses the research findings presented in Chapter Four, in relation 
to the aims of the research and the literature review, and draws a summary as to 
the prevalence of the risk-factors, the association between the presence of these 
risk-factors and the participants’ cervical screening attendance and abnormal 
screening results, and participants’ key barriers to cervical cancer prevention.   
 
Chapter Six draws a conclusion as to the present research study and presents 









2.1 Introduction  
This chapter presents the rationale for young women to attend for cervical 
screening in the prevention of cervical cancer, by examining the risk-factors for 
developing cervical cancer and the prevalence of these risk-factors.  Firstly, the 
incidence of cervical cancer is noted and the context for cervical screening in the 
prevention of cervical cancer is examined.  Next, the relationship between the 
Human Papillomavirus (HPV) and cervical cancer is explored, focusing on the 
risk-factors for contracting HPV and developing cervical cancer (International 
Agency for Research on Cancer, 2003, 2005).  The prevalence of these risk-factors 
is then briefly considered among young women in the Irish and where possible, 
international context, drawing on recent epidemiological studies.  Afterwards, the 
key barriers to the prevention of cervical cancer are examined, focusing on the 
impact that knowledge has on cervical cancer prevention.  The initiation of 
cervical screening in different countries is then concisely contemplated in relation 
to international guidelines, and lastly, a summary is drawn.  
 
2.2 Cervical Cancer: Prevalence, Screening, Prevention and Treatment 
Cancer of the cervix uterine, the neck of the womb (see Appendix C) (Schiffman 
et al, 2007; Shafi and Welton, 2007), develops when abnormal cervical cells begin 
unrestrained multiplying and form precancerous lesions (Department of Health 
and Ageing, Australian Government, 1991).  Second only to breast cancer, cervical 
cancer is the most prevalent cancer among women worldwide (International 
Agency for Research on Cancer, 2003, 2005).  Approximately 500,000 new cases 
and 270,000 deaths from cervical cancer occur annually; 80% of which occurs in 
developing countries (ibid).  In Ireland, approximately 1,000 new cases of 
preinvasive and 180 new cases of invasive cervical cancer are diagnosed each 
year, whilst annually over 80 women die from cervical cancer, 70% of whom had 
not attended for regular cervical screening (Women's Health Council, 2006, in 
Martin et al, 2007; Irish Cervical Screening Programme, 2004a, 2004c, 2007; 
Department of Health and Children, 2006; Irish Cancer Society, 2006).  This is one 
of the highest rates in Western Europe, with mortality rising annually by 1.5% 
(Prendiville, 2007; Comber and Gavin, 2004).  
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Epidemiological studies show consistent associations between the risk of cervical 
cancer, infection with HPV and sexual behaviour (these associations will be 
subsequently discussed), yet, secondary prevention remains the principal strategy 
for the prevention of cervical cancer (Muñoz et al, 1992a, 1992b in International 
Agency for Research on Cancer, 2003, 2005).  The secondary prevention of 
cancer involves the opportunistic or population-based screening of individuals to 
detect (preinvasive) cancer at a stage when curative treatment is still possible, 
whereas primary prevention aims to avoid the development of cancer by reducing 
or eliminating exposure to the risk-factors that are known to cause cancer 
(International Agency for Research on Cancer, 2003; Sikora, 2007; Hakama et al, 
2008).  Therefore, the objective of cervical screening is to  
 
reduce the mortality from (and incidence of) the disease by 
identifying women with precancerous cervical lesions and early 
invasive cancers, and treating these women appropriately 
(International Agency for Research on Cancer, 2005, p. 9). 
   
It is these precursors of invasive cervical cancer that are screened for, rather than 
the cancer itself, as these lesions have in principle, the capacity to progress to 
invasive cervical cancer if left untreated (Shafi and Welton, 2007; International 
Agency for Research on Cancer, 2005).  Although cervical cancer is always a 
potentially lethal disease, its preinvasive stage, “during which the disease can be 
treated so that its progression to overt disease is stopped”, is 3-10 years (Cole and 
Morrison, 1978, in Hakama et al, 2008, p. 1404; Shafi and Welton, 2007; 
Kitchener et al, 2008; Government of Ireland, 1996).   
 
Cervical screening, also known as a cervical smear test or a papanicolaou (PAP) 
smear, takes approximately five minutes and involves a registered smeartaker (a 
specifically trained nurse or doctor) scraping cells from the surface of the 
woman's cervix; these cells are then sent to a cervical cytology laboratory to be 
microscopically examined for precancerous cervical cell abnormalities (Irish 
Cancer Society, 2008; Ni Riain et al, 2003; Nevid et al, 1995).  As there is no 
single European classification system, abnormal cervical screening results, 
representing a continuum risk for invasive cervical cancer, are classified in Ireland 
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using Cervical Intraepithelial Neoplasia (CIN) or Bethesda terminology 
(International Agency for Research on Cancer, 2005; Bano et al, 2008; Castle et 
al, 2007; Irish Cervical Screening Programme, 2004b).  There are three CIN grades 
(I, II and III) corresponding to mild, moderate and severe dyskaryosis (see 
Appendix D) (Government of Ireland, 1996; International Agency for Research 
on Cancer, 2005).  Additionally, ‘borderline nuclear abnormalities’ (BNA) 
describes uncertain cervical cell abnormalities not yet classifiable under CIN 
(Kitchener et al, 2006).  It is estimated that 84% of (Irish) smears are normal or 
negative for CIN, 6% report abnormalities and 10% are inadequate, meaning that the 
smear does not give an accurate result (Ni Riain et al, 2003; McGoogan, 2004; 
Leeson, 2005).  
 
The assessment of abnormal screening results and the prevention of cervical 
cancer in the majority of (developed) countries, including Ireland, conventionally 
involves three-stages: a smear test, colposcopy/biopsy and treatment (see 
Appendix E) (Bosch et al, 2008; Kitchener et al, 2006; Ni Riain et al, 2003; 
McGoogan, 2004).  These three-stages are dictated by specific management 
protocols (see Appendix F) (ibid).  Since approximately one-third of lesions will 
spontaneously regress without treatment, these protocols aim to prevent the over-
diagnosis and over-treatment of cervical lesions (Hakama et al, 2008; European 
Cervical Cancer Screening Network, 2003; International Agency for Research on 
Cancer, 2003).  However, as two-thirds of lesions will persist or progress to a 
higher grade of CIN, at the progression rate of 3-5 years per grade, these protocols 
also prescribe the management of abnormal cervical screenings (Ni Riain et al, 
2003; Shafi and Welton, 2007).  Persistent lesions require a colposcopy, whereby 
the cervix is viewed under a microscope, followed by a biopsy of the abnormal 
cervical cells for further cervical cytology (microscopic examination) (Ni Riain et 
al, 2003; Government of Ireland, 1996).  Consequently, as cervical screening only 
detects changes in the cervical cells (Leeson, 2005), the assessment of abnormal 
screenings and the selection of those necessitating treatment, depends primarily 
on their colposcopy and biopsy findings (Shafi and Welton, 2007; Irish Cervical 
Screening Programme, 2005a).   
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Where preinvasive cervical cancer (CIN2/3) is diagnosed, ablative (removal) 
treatment procedures are employed in Ireland: the ‘laser loop excision of the 
transformation zone’ (LLETZ) excisions the required area with least morbidity, 
while a cone biopsy involves the “surgical removal of a cone-shaped section of the 
cervix to remove abnormal cells” and is associated with cervical stenosis and 
incompetence (Ni Riain et al, 2003, p. 66; Cancerbackup, 2007; Leeson, 2005 
Spitzer, 2007; Stanley, 2008).  These procedures necessitate approximately six 
weeks healing time for the cervix, yet, as the precancerous lesions are fully removed 
in approximately 90% of women, these treatments may be more accurately viewed 
as cancer risk-reducing interventions (Castle et al, 2007; McGoogan, 2004; 
Kitchener et al, 2006; Cancerbackup, 2007).  Conversely, where invasive cervical 
cancer (CIN3+) is diagnosed and depending on the stage of cancer and whether 
fertility is desired, treatments may comprise: hysterectomy, chemotherapy and 
dual treatment with both radiation and surgery (Ni Riain et al, 2003; Spitzer, 
2007; Shafi and Welton, 2007). 
 
Therefore, as the chief hindrance in preventing cervical cancer is a failure to be 
screened at all, the International Agency for Research on Cancer (IARC), part of 
the World Health Organisation (WHO), asserts that a fully competent organised 
national cervical screening programme could result in an 80% mortality reduction, 
as opportunistic screening tends to miss women at greatest risk (International 
Agency for Research on Cancer, 2003, 2005; Albreht et al, 2008).  In 2000, a pilot 
project of the Irish Cervical Screening Programme (ICSP) was launched entitling 
women aged 25-60 to free cervical screening at five-year intervals (Irish Cervical 
Screening Programme, 2004a; Irish Cervical Screening Project, 2003, in Comber 
and Gavin, 2004).  The ICSP, now incorporated into ‘CervicalCheck- The 
National Cervical Screening Programme’, had aimed to be national by January 
2006 (Department of Health and Children, 2006; Government of Ireland, 2001), 
but is only being initiated nationwide since September 2008 (Irish Cervical 
Screening Programme, 2008a, 2008b).  Consequently, the absence of an organised 
national cervical screening programme has contributed to Ireland’s rising cervical 
cancer mortality rate, as opportunistic screening remained the only option for the 
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majority of Irish women (Comber and Gavin, 2004; Treanor et al, 2002; 
Prendiville, 2007).  
 
2.3 The Human Papillomavirus (HPV), Cervical Cancer and the Risk-Factors 
HPV is an extremely common sexually transmitted virus that approximately 80% 
of individuals will be infected with at some stage in their lives, although the 
majority of individuals will spontaneously clear HPV infections within two years 
of being infected (Scheurer et al, 2005, in Martin et al, 2007; Shafi and Welton, 
2007; Martin et al, 2007; Leeson, 2005).  Over 200 HPV strains have been 
identified, 40 of which infect the genital tract, for example, ano-genital warts; of 
these, 15 are considered high-risk or oncogenic for cervical cancer (Walboomers 
et al, 1999, in Myers et al, 2008; Stanley, 2008; International Agency for 
Research on Cancer, 2003, 2005; Schiffman et al, 2007).  As HPV infection is 
evident in over 99% of cervical cancer specimens, persistent oncogenic HPV 
infection in the cervical transformation zone (TZ) (see Appendix C) is established 
as the aetiological cause of cervical cancer and CIN (Walboomers et al, 1999, in 
International Agency for Research on Cancer, 2003, 2005; zur Hausen, 1999, in 
International Agency for Research on Cancer, 2003; Kjaer et al, 2002).  HPV 
persistency takes 2-15 years, signifying that preinvasive cervical cancer can be 
detected within three years of HPV infection (Kitchener et al, 2006; Woodman et 
al, 2001, in Sasieni and Castanon, 2006; Mao et al, 2006, in Harper and Paavonen, 
2008).  
  
The risk-factors for HPV infection are well-established through epidemiological 
studies, as being related to one’s sexual behaviour; specifically, the age at first 
sexual intercourse and increasing numbers of sexual partners for females and their 
sexual partners (see Appendix G) (Muñoz et al, 1992a, 1992b, in International 
Agency for Research on Cancer, 2005; Bosch et al, 2002).  The age of first sexual 
intercourse, at the age of peri-menarche or approximately age 17, is linked partly 
to the age at first HPV exposure, but primarily to the opinion that the developing 
cervix is at high-risk for HPV infection to establish persistency (Bosch et al, 2002; 
Todd and Shafi, 2004).  In recent Irish research, 62% of young women with 
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preinvasive cervical cancer debuted sexually before age 14 (O’Connor et al, 
2008).  Furthermore, increasing numbers of sexual partners enhances the 
likelihood of concurrent HPV infections with multiple HPV types and the 
probability of persistent oncogenic HPV infection (Schiffman et al, 2007; Deacon 
et al, 2000; International Agency for Research on Cancer, 2005).  Research 
demonstrates that women reporting over nine sexual partners had a HPV 
incidence rate of 69% (Ley et al, 1991, in Moscicki, 2005).  Yet, sex with only 
one partner and a lack of knowledge about a partner’s prior sexual experiences is 
also associated with HPV infection, especially where the partner has had several 
other sexual partners (Moscicki, 2005; Winer et al, 2003).  Consequently, the 
abovementioned sexual behaviour risk-factors also reflect the probability of 
becoming infected with HPV (International Agency for Research on Cancer, 
2003).  
 
Sexually transmitted infections (STIs), especially HPV associated ano-genital 
warts, are also considered risk-factors, as they cause inflammation of the cervix, 
allowing the HPV infection direct access to the cervical cells, thus promoting 
HPV persistency (Moscicki, 2005; Bosch et al, 2002; Todd and Shafi, 2004; 
International Agency for Research on Cancer, 2003, 2005).  Irish research 
demonstrated that 80% of young Irish women presenting with CIN3, also had 
chlamydia (O’Connor et al, 2008).  Additionally, STIs negatively affect one’s 
immune system, reducing the likelihood of clearing HPV infection (Shafi and 
Welton, 2007; Bosch et al, 2002).  
 
 
However, since only a small fraction of HPV-infected women will 
eventually develop cervical cancer, there must be other exogenous 
or endogenous factors which, acting in-conjunction with HPV, 
influence the progression from cervical infection to cervical cancer 
(International Agency for Research on Cancer, 2003, p. 216).   
 
These factors are smoking and long-term (more than five years) use of oral 
contraceptives (OC), as they increase about fourfold and twofold respectively, the 
risk of developing cervical cancer (Ni Riain et al, 2003; International Agency for 
Research on Cancer, 2003, 2005; International Collaboration of Epidemiological 
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Studies of Cervical Cancer, 2007).  OC are considered co-factors, as they 
influence infection and enhance the effect of oestrogens on cervical cells, directly 
inducing and increasing the “cell proliferation and transcription of HPV”, whilst 
permitting HPV easier access to the TZ (de Villiers, 2003, in Cotton et al, 2007, p. 
138; Green et al, 2003, in Cotton et al, 2007).  Yet, OC use itself does not 
automatically indicate cervical cancer causation; firstly, in developed countries, 
women using OC typically have increased cytological surveillance (hence the 
association) (Bosch et al, 2002; International Collaboration of Epidemiological 
Studies of Cervical Cancer, 2007) and secondly, women using OC “are more 
likely to be exposed to HPV than are those using barrier methods” (Sasieni, 2007, 
p. 1591).   
  
Studies investigating the effects of tobacco smoking show that the risk of 
developing (cervical) cancer rises with increasing exposure to smoking;  
 
smokers were found to maintain cervical HPV infections 
significantly longer and to have a lower probability of clearing an 
oncogenic infection than women who never smoked (Giulian et al, 
2002, in International Agency for Research on Cancer, 2005, p. 43; 
Deacon et al, 2000). 
   
Specifically, HPV-infected women who smoke 20 cigarettes or more a day, have a 
significant risk of progressing to a higher CIN grade; 2.5 times that of women 
who have never smoked, in addition to a threefold increased risk of CIN treatment 
failure (Shafi and Welton, 2007; Aclaudious et al, 2002, in Frega et al, 2003).  
Furthermore, a smoking reduction intervention study among women with minor-
grade lesions resulted in a reduction in lesion size, further supporting the role of 
smoking in HPV carcinogenesis (Szarewski et al, 1996, in International Agency 
for Research on Cancer, 2005; Shafi and Welton, 2007).  Other co-factors under 
evaluation for increasing the risk of developing cervical cancer include 
multiparity, nutritional factors and socioeconomic status (Bosch et al, 2002; Akers 
et al, 2007).   
 
A recent development in the primary prevention of cervical cancer is the use of 
HPV-type 16/18 vaccines, ‘Gardasil’ and ‘Cervarix’, as these HPV strains are 
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responsible for approximately 70% of cervical cancers (International Agency for 
Research on Cancer, 2003, 2005; Myers et al, 2008; Bosch et al, 2002; 
Kulasingam et al, 2007).  Since 2007, the Australian Government provides HPV-
vaccination free to females aged 12-13, via a school-based immunisation delivery 
programme (Stanley, 2008; Franco and Cuzick, 2008); the United Kingdom (UK) 
proposes to offer the same beginning September 2008 (UK Joint Committee on 
Vaccination and Immunisation, 2007, in Stanley, 2008), as will the Irish 
Department of Health commencing September 2009 (Houston, 2008).  However, 
concerns exist that HPV-vaccinated females will be less likely to attend for 
cervical screening, due to a belief that vaccination offers complete cervical cancer 
prevention, even though at the time of publication, no HPV-vaccine had a life-
long duration or provides cross-protection against all oncogenic HPV types 
(Kulasingam and Myers, 2003, in Myers et al, 2008; Goldie et al, 2004, in Myers 
et al, 2008; Kulasingam et al, 2007; Stanley, 2008; Prendiville, 2007; Harper and 
Paavonen, 2008).  Nevertheless, as HPV-vaccines are administered prior to sexual 
debut, vaccination should help address inconsistencies such as the age at which to 
begin screening (Myers et al, 2008; Stanley, 2008; Kulasingam et al, 2007).  
Furthermore, although beyond the scope of this paper, advances have been made 
in HPV testing as a primary screening test to detect persistent oncogenic HPV 
infection, before changes in the cervical cells are detectable through cervical 
screening (Franco and Cuzick, 2008; Castle et al, 2007; International Agency for 
Research on Cancer, 2003, 2005; Prendiville, 2007).   
  
Therefore, as the probability of developing preinvasive cervical cancer becomes 
appreciable only when persistent oncogenic HPV infection occurs, the 
abovementioned risk-factors can be used to help characterise an individual 
woman's risk (Castle et al, 2007; International Agency for Research on Cancer, 





2.4 The Prevalence of the HPV and Cervical Cancer Risk-Factors among Young 
Women in the Irish Context 
In Ireland, the prevalence of the risk-factors for contracting HPV and developing 
cervical cancer are becoming gradually more common, due to the increasingly 
liberal views of sexuality that many young people hold; approximately 83% of 
young people are sexually active (Malesevic, 2003; Schubotz et al, 2002; Cousins 
et al, 2008l Layte et al, 2006).  The legal age for heterosexual and homosexual 
intercourse in Ireland is 17 (Rundle et al, 2008), yet the demographically 
representative ‘Irish Study of Sexual Health and Relationships’ (ISSHR), reported 
that 31% of young men and 22% of young women had sexual intercourse before 
age 17 (Layte et al, 2006).  This study also noted that the mean age for sexual 
debut was 16.9 for young men and 17.4 for young women (ibid).  Thus, as the 
mean age for sexual debut was 21 in the 55-64 age cohort, with only 11% of men 
and 2% of women reporting intercourse before age 17, the average age for first 
sexual intercourse is decreasing (Rundle et al, 2008; Layte et al, 2006; Lalor et al, 
2007).  These findings are consistent with international research; in America, the 
mean age of sexual debut was approximately 17 (Mosher et al, 2002, in Castle et 
al, 2007), while in the UK it was 16, down from 21 years-of-age in the 1950s 
(Wellings et al, 2005, in Sasieni and Castanon, 2006).   
 
The ISSHR found that the average number of female sexual partners (LSP) for 
young men was 6: 35% reported 1 LSP, while 21% reported 10 or more LSP 
(Layte et al, 2006; McGee et al, 2008).  For young women, the average number of 
male sexual partners (LSP) was 4: 50% reported 1 LSP, while 8% reported more 
than 10 LSP (ibid).  In comparison, 53% of men and 82% of women within the 
55-64 age cohort reported 1 LSP, while 8% of men and only 2% of women in the 
same cohort reported more than 10 LSP, demonstrating that the average number 
of sexual partners is increasing (ibid).  The ISSHR figures for same-sex 
partnerships were similar in all age cohorts, although they could not be verified 
for young people (McGee et al, 2008).   
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Additionally, the ISSHR noted that 94% of sexually active young women reported 
always using contraceptives: 46% reported using the oral contraceptive pill (OCP) 
(McGee et al, 2008; Layte et al, 2006; Cousins et al, 2008).  The Irish 
Contraception and Crisis Pregnancy study reported slightly higher findings, 
whereby 55% of young women reported OCP use (Rundle et al, 2004, in Cousins 
et al, 2008; Shiely et al, 2004).  In contrast, only 24% of young women in the UK 
reported consistent OCP use (Botting and Dunnell, 2000, in Peto et al, 2004).   
 
In Ireland, the incidence of smoking among 18-34 year-olds was 34% (Central 
Statistics Office, 2002).  More specifically, Irish research found that 19% of 
young people classified themselves as smokers (Currie et al, 2003, in Lalor et al, 
2007), with young women having higher rates of current and lifetime smoking 
than young men (HSE, 2003, in Lalor et al, 2007).  International research reports 
similar findings; in the UK, female smoking stands at 26% (Office for National 
Statistic, 2002, in Peto et al, 2004; Sierra-Tores et al, 2003, in Bano et al, 2008).  
 
Further related to the risk-factors for developing cervical cancer, the ISSHR noted 
that 2% of young men and 2.6% of young women reported being diagnosed with an 
STI (McGee et al, 2008; Cousins et al, 2008; Layte et al, 2006).  Moreover, the 
incidence of ano-genital warts, “the clinically visible manifestation of infection 
with HPV” (Health Protection Surveillance, 2008a, p. 1), has increased tenfold in 
Ireland since 1989 and is now the most commonly reported STI; 78% (2,726) of 
reported cases occurred in individuals aged under 29 (National Disease Surveillance 
Centre, 2001, in Comber and Gavin, 2004; Health Protection Surveillance, 2008b).  
These statistics are mirrored in Australia (Grulich et al, 2003, in McGee et al, 2008) 
and the UK, whereby 50% of all reported STIs occurred in young people, of which 
ano-genital warts/HPV was most commonly reported (Weinstock et al, 2004, in 
Moscicki, 2005; Collins et al, 2002, in Bano et al, 2008).  Consequently, these 
studies indicate that STIs, particularly among young people, are increasing (Gilson 
and Mindel, 2001).   
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The increases in the prevalence of the aforementioned cervical cancer risk-factors 
and especially in HPV diagnoses, suggests a high transmission and infection rate 
of HPV among young people (Leeson, 2005; Harper and Paavonen, 2008; 
International Agency for Research on Cancer, 2003).  Approximately 40% of 20-
year-old women are estimated to be HPV-positive at any one time, 10% of which 
are oncogenic HYP types, while 55% of young people who become HPV-
positive, do so within three years of sexual debut (Leeson, 2005; Harper and 
Paavonen, 2008; Moscicki, 2005; Winer et al, 2003; Collins et al, 2002, in Bano 
et al, 2008).  In Ireland, Keegan and colleagues (2007) revealed that 31% of 
opportunistically screened young women were HPV-positive, reducing steadily to 
11% of women aged over 35 (Keegan et al, 2007; Cuschieri et al, 2004, in Keegan 
et al, 2007).  This corresponds to international research which indicates that whilst 
young women have the highest acquisition and prevalence rate of oncogenic HPV, 
non-persistent HPV infections decrease with age (Harper and Paavonen, 2008; 
Shafi and Welton, 2007; Cuzick et al, 2003, in Cotton et al, 2007; Winer and 
Koutsky, 2004, in Cotton et al, 2007).   
 
Nonetheless, in Ireland, HPV prevalence was found to increase with CIN grade, 
from 11% in normal screening results, to 100% in CIN2/3 results (Keegan et al, 
2007; Cuschieri et al, 2004, in Keegan et al, 2007).  This is comparable to 
international research, whereby 93% of women aged under 29 with high-grade 
cervical abnormalities and 89% with low-grade abnormalities were also HPV-
positive (Kjaer et al, 2002).  Additionally, in Ireland in 2000, young women 
accounted for 23% of CIN2/3 findings, an increase from 14% in 1997, even 
though this age group represented just 17% of all smears (Treanor et al, 2002).  
This is in contrast to the over-55 age group which accounted for just 3% of 
CIN2/3 findings in 2000 (Treanor et al, 2002).  Furthermore, in 2005 (the most 
recent data available), women aged under 25 demonstrated the third-highest age-
specific incidence rate of CIN3, at 1.72 per 1,000, a massive increase from 0.48 in 
1995 (see Appendix B) (National Cancer Registry Ireland, 2006; Treanor et al, 
2002).   
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These studies correspond to evidence that as the prevalence of the risk-factors for 
contracting HPV and developing cervical cancer are increasing among young Irish 
women, so to are cervical abnormality incidences, especially preinvasive cervical 
cancer (Keegan et al, 2007; Treanor et al, 2002), thus demonstrating the necessity 
of including young women in routine cervical screening (Bano et al, 2008; 
Treanor et al, 2002).      
 
2.5 The Key Barriers to Cervical Cancer Prevention  
In Ireland, cervical cancer is currently prevented through secondary prevention; 
namely, cervical screening (International Agency for Research on Cancer, 2003; 
Ni Riain et al, 2003).  
 
Studies indicate that in general, women are aware of the need to 
have a smear test, however, because of the barriers identified, are 
often reluctant to have one (Neilson and Jones, 1998, in Irish 
Cervical Screening Programme, 2004c, p. 22).   
 
The barriers to cervical screening encompass both personal and practical barriers 
(Irish Cervical Screening Programme, 2004c).  Personal barriers, comprising 
emotional barriers relating to the woman herself, include: embarrassment, ‘don’t 
think I need a cervical smear test, and ‘don’t know where to go to get a cervical 
smear test’ (ICSP Barometer Survey, 2004, in Irish Cervical Screening 
Programme, 2004c; Irish Cancer Society, 2006).  These barriers are supported by 
Irish and international research which noted other personal barriers such as: 
‘concerns about having a male smeartaker’, ‘fear of the screening process’ and 
‘fear of what might be found’ (Walsh et al, 2003; Walsh, 2006; Irish Cancer 
Society, 2006; Ni Riain et al, 2003; Fylan, 1998).  Furthermore, ‘uncertainty 
about what age to begin screening’, ‘fear of pain’, considering oneself not to be at 
risk of developing cervical cancer, ‘don’t know what a cervical smear test is for’, 
and previous negative experiences with the health service, are also deterrents to 
screening (Ni Riain et al, 2003; Summers and Fullard, 1998, in Fylan, 1998; Irish 
Cancer Society, 2006; MacGregor et al, 1994, in Fylan, 1998).  Ethnic 
differences, such as language barriers, may also deter women from attending for 
cervical screening (Ni Riain et al, 2003).  
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Conversely, the practical barriers to cervical screening relate to the availability of 
screening and the woman's perception about the importance of cervical screening, 
which in turn influences her attitudes towards screening (Irish Cervical Screening 
Programme, 2004c; Philips et al, 2003).  The practical barriers are established by 
research as including: a lack of time, concerns about the cost of screening, 
unsuitable appointment times, a lack of access and fears about confidentiality (Ni 
Riain et al, 2003; Irish Cancer Society, 2006; The ICSP Barometer Survey, 2004, 
in Irish Cervical Screening Programme, 2004c; Walsh et al, 2003; Walsh, 2006).  
An additional practical barrier to screening is a common perception by women 
that if they are not offered a smear test by their health-provider, then they do not 
need one (Hennig and Knowles, 1990, in Irish Cervical Screening Programme, 
2004c; Irish Cancer Society, 2006).   
 
As evident, these barriers to screening are typically related to a woman's lack of 
knowledge about secondary cervical cancer prevention; such as not knowing that 
a cervical smear test can help prevent cancer (Irish Cervical Screening 
Programme, 2004c; Philips et al, 2003).  A lack of knowledge by women and their 
healthcare-providers about the meaning of a cervical smear test result can also 
compound barriers to screening: for example, by misinterpreting a positive (for 
CIN) result as indicating cancer, or a negative result as indicating no risk of 
cervical cancer, instead of a low risk (World Health Organisation, 2005, in Sasieni 
and Castanon, 2006; International Agency for Research on Cancer, 2005; Marteau 
et al, 2001; Fylan, 1998).  Furthermore, a misunderstanding of the concept of 
‘precancerous lesion’ or receiving an ‘abnormal’ result may cause psychological 
distress including anxiety and concerns about future fertility (Lerman et al, 1991, 
in Kahn et al, 2001; Rosgrad, 2002, in Chew-Graham et al, 2006; Karasz et al, 
2003, in Chew-Graham et al, 2006).  In addition, embarrassment, stigma and 
lowered self-esteem may also be felt with an ‘abnormal’ result, as the association 
between HPV and cervical cancer may be interpreted by some women as 
indicating promiscuity (McKie, 1993, in International Agency for Research on 
Cancer, 2005; Posner and Vessey, 1988, in Kitchener et al, 2006).  
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Research in Ireland has indicated that the majority of women have limited 
knowledge of the purpose of a cervical smear test and of the meaning of cervical 
screening results, thus amplifying their anxiety and fear about cervical screening 
(Cotter et al, 1999, in Martin et al, 2007; Alder and Foxwell, 1999, in Walsh, 
2006).  For example, when asked a series of questions about the purpose of a 
cervical smear test, 50% of Irish women believed it detected infection/STIs, 78% 
thought that it detected cervical cancer and 70% (correctly) stated that a cervical 
smear test detected changes in the cells of the cervix; only 1% did not know the 
purpose of a cervical smear test (Walsh et al, 2003; Walsh, 2006).  Not 
surprisingly, 37% of Irish women reported feeling that they did not know enough 
about cervical screening (ibid).  Nevertheless, research approximates that over 
half of women can correctly identify a ‘normal’ smear test result as meaning a low 
risk of cervical cancer, although roughly 9% believe a normal result means no risk 
of cervical cancer (Cotter et al, 1999, in Martin et al, 2007).  Furthermore, 
demographically representative research by the Irish Cancer Society demonstrated 
that two-thirds of women aged 20-30 have never had a cervical smear test; 40% of 
whom claimed a low level of knowledge about cervical cancer prevention 
(Cervical Screening & Cancer Awareness and Attitudes Survey, 2006, in Irish 
Cervical Screening Programme, 2007; Irish Cancer Society, 2006).   
 
Research has also demonstrated that women have little knowledge of the primary 
prevention of cervical cancer, specifically the association with HPV (Summers 
and Fullard, 1998, in Fylan, 1998; Stark et al, 2008; Marlow et al, 2007).  Despite 
the high prevalence of HPV, studies range from 20% of young people (Irish 
Cancer Society, 2006) to 75% of third-level students having ‘heard of’ HPV 
(Gerend and Magloire, 2008).  These latter students also correctly identified HPV 
risk as associated with being sexually active and having many sexual partners, 
albeit 64% of participants wanting to know more about HPV (ibid).  Additionally, 
research shows that sexually active young women have a low awareness of the 
high risk for contracting HPV and therefore, a low knowledge of primary cervical 
cancer prevention (Frega et al, 2003; Yacobi et al, 1999, in Frega et al, 2003), 
 17
even though 17% of female third-level students are estimated to have attended for 
cervical screening (Philips et al, 2003).   
 
Studies have demonstrated that improved communication, education and 
information on the primary and secondary prevention of cervical cancer, 
specifically regarding the transmission of HPV and the importance of cervical 
screening, increases the probability of screening by counteracting the anxieties 
and fears that are key barriers (Wilkinson et al, 1990, in Kitchener et al, 2006; 
Ronco et al, 1994, 1999, in International Agency for Research on Cancer, 2005; 
Eaker et al, 2001a, 2001b, in International Agency for Research on Cancer, 2005; 
O’Malley et al, 2002, in International Agency for Research on Cancer, 2005; Irish 
Cancer Society, 2006).  Additional education has also been found to increase the 
uptake of preventative cervical screening, by improving understanding of 
information, communication and accessibility to services (see Appendix H) 
(Sabates and Feinstein, 2006; Fylan, 1998).  Consequently, sufficient knowledge 
helps encourage a good communicative relationship (Kahn et al, 2001) and may 
reduce the likelihood of the smeartakers gender acting as a barrier to screening 
and a deterrent to communication (Roter and Hall, 1992, in Kahn et al, 2001; 
Girgis et al, 1996, in Irish Cervical Screening Programme, 2004c).  Increased 
knowledge may also, at least in the short-term, influence the potentially 
controllable behavioural factors that increase a woman's risk of developing 
cervical cancer, namely possible risky sexual behaviours and smoking (Philips et 
al, 2003).  Additionally, as attitudes to screening are linked to perceptions about 
its importance, increased knowledge may lead to a change in individual valuations 
of screening and the adoption of preventative health behaviours, such as 
compliance with follow-up appointments (Philips et al, 2003; Kahn et al, 2001). 
 
It is important however, that women are given unbiased, accurate information on 
the processes, consequences and benefits of screening, including the fact that 
screening cannot prevent all cases of pre- or invasive cancer (International 
Agency for Research on Cancer, 2005).  This allows young women to make an 
informed choice of whether to attend for screening, based on the presence of the 
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risk-factors for developing cervical cancer, rather than simply using the woman's 
biological age to determine her entitlement to cervical screening (International 
Agency for Research on Cancer, 2005; Barry et al, 2007; Irwig et al, 2006; Philips 
et al, 2003; Castle et al, 2007).  Consequently, such knowledge also helps ensure 
that healthcare-providers respect patient autonomy in decision-making and 
contributes to equity of access, whereby smeartakers have an ethical responsibility 
to provide screening to those whose sexual and behavioural history warrants 
cervical screening (International Agency for Research on Cancer, 2005; Irwig et 
al, 2006; Entwistle et al, 1998, in Philips et al, 2003).  
 
For these reasons, there is a need to impart knowledge, regarding the primary and 
secondary prevention of cervical cancer, within educational programmes (Irish 
Cancer Society, 2006; Walsh et al, 2003).  In 1997, the Relationships and 
Sexuality Education Programme (RSE) was introduced into Irish schools “to 
provide young people with a holistic understanding of sexuality in the context of 
relationships” (Cousins et al, 2008, p. 9).  However, the ISSHR reported that 
approximately 18% of young people received no sex education in school (Rundle 
et al, 2008; Layte et al, 2006).  Furthermore, although RSE is mandatory in 
schools, discretion is provided regarding the content of its teaching; there is no 
onus to provide education on the primary or secondary prevention of cervical 
cancer, respectively, the HPV risk-factors and cervical screening (Hyde and 
Howlett, 2004; Rundle et al, 2008; Department of Education, 1997).  Rundle and 
colleagues (2008) argue that such discretion and the fact that the proportion of 
adolescents receiving RSE decreases as they progress through school, suggests 
that many young people may not have received adequate sex education (Rundle et 
al, 2008; Maycock et al, 2007; Cousins et al, 2008).  For example, approximately 
80% of young people reported a lack of information regarding STIs within formal 
sex education (Hyde and Howlett, 2004).  Consequently, there is a need to provide 
comprehensive academic sex education, incorporating information on cervical 
cancer and the associated risk-factors, that is also easily transferable to public 
educational programmes (Martin et al, 2007; Irish Cancer Society, 2006).  
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2.6 International Cervical Screening Programmes  
Worldwide and European guidelines differ regarding the age at which to initiate 
cervical screening (Hakama et al, 2008; European Union, 2003).  The IARC 
recommends that 
 
organised [cervical screening] programmes should not include 
women aged less than 25 years in their target populations 
(International Agency for Research on Cancer, 2005, p. 240),  
 
while European guidelines recommend that cervical screening commences 
“definitely not before the age of 20” (European Commission, 2003, as cited in 
Sasieni and Castanon, 2006, p. 118).  Their rationale is that firstly, as the 
incidence of invasive cervical cancer among women aged under 20 is low, the 
probability that abnormalities will progress to cervical cancer is also low 
(International Agency for Research on Cancer, 2005; Stoler and Schiffman, 2001, 
in Myers et al, 2008; Sasieni and Castanon, 2006), and secondly, that aggressive 
treatment (LLETZ or cone biopsy) of cervical lesions in such women, increases 
the risk of subsequent adverse obstetric outcomes, such as preterm delivery 
(Kyrgiou et al, 2006, in Myers et al, 2008; Kyrgiou et al, 2006, in Prendiville, 
2007; Sadler et al, 2004, in Moscicki, 2005; Bruinsma et al, 2007, in Bano et al, 
2008).  Nevertheless, both guidelines advocate screening every 3-5 years, as this 
provides effective cover inline with the progression rates of CIN (European 
Commission, 2003, in Sasieni and Castanon, 2006; International Agency for 
Research on Cancer, 2005; Shafi and Welton, 2007; Leeson, 2005).  
 
American cervical screening guidelines recommend that annual screening begins 
“at age 21 or 3 years after sexual debut, whichever comes first” (American Cancer 
Society, 2007, in Myers et al, 2008, p. 34; the American College of Obstetricians 
and Gynecologists, 2002, in Spitzer, 2007; the US Preventative Services Task 
Force, no year, in Myers et al, 2008).  These recommendations are founded on 
research which concludes that,  
 
young women are especially susceptible to infection with HPV [as] 
they are more sexually active with more partners … [yet] most 
HPV-related lesions in young women regress within three years 
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(the National Cancer Institute’s Surveillance, Epidemiology and 
End Results Programme, 1995-1999, in Spitzer, 2007, p. 18);  
 
hence the phrasing, “or 3 years after sexual debut” (American Cancer Society, 
2007, in Myers et al, 2008, p. 34).  Notably, these recommendations have resulted 
in a 94% reduction in the cumulative incidence of invasive cervical cancer (see 
Appendix J) (Benard et al, 2001, in Akers et al, 2007), and are similar to 
Australia’s national cervical screening programme, which advocates that all 
women who have had sexual intercourse, attend from ages 18-20 or within two 
years of sexual debut, whichever is later, biannual screening (Department of 
Health and Ageing, Australian Government, 1991).    
 
In 1988, inline with long-term research reporting a lower average age for sexual 
debut and increased numbers of sexual partners, STIs and HPV, Iceland’s 
organised cervical cancer screening programme commenced biannual screening 
from age 20 (Peto et al, 2004, in Sigurdsson and Sigvaldason, 2007; Sigurdsson, 
1993, in Sigurdsson and Sigvaldason, 2007).  Although this approach is not in 
keeping with the IARC guidelines, Sigurdsson and Sigvaldason (2007) revealed 
that 37% of CIN2/3 lesions in the period 1999-2003, occurred in the 20-24 age 
group, thus supporting screening initiation before age 25.  Their research also 
demonstrated significantly increased detection rates of preinvasive cervical cancer 
in women aged under 29 (ibid), corresponding to data from Ireland (National 
Cancer Registry Ireland, 2006), the UK (Miller, 2002, in Sigurdsson and 
Sigvaldason, 2007; Department of Health, 2003, in Sasieni and Castanon, 2006), 
the Nordic countries (Sigurdsson, 1995, in Sigurdsson and Sigvaldason, 2007; 
Antilla et al, 1999, in Sigurdsson and Sigvaldason, 2007) and America (Dunn and 
Martin, 1967, in International Agency for Research on Cancer, 2005).  
Conversely, in other countries where cervical screening also continues until 
approximately age 60, the instigation of population-based screening differs: 
Finland and the Netherlands begin screening at age 30; the UK, Spain, Belgium, 
France, Italy, Ireland and Norway at age 25; New Zealand, Canada, Japan, 
Sweden, Germany and Austria at age 20; and Luxembourg from age 15 
(International Agency for Research on Cancer, 2005; Sasieni and Castanon, 2006; 
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Spitzer, 2007; Schaffer et al, 2000).  However, all countries endorse a maximum 
screening interval of five years, in accordance with international 
recommendations (International Agency for Research on Cancer, 2005).   
 
As a result of national screening programmes in the majority of the 
abovementioned countries (except Ireland), a reduction in mortality from cervical 
cancer has occurred by up to 80% (see Appendix J) (WHO, 1986, in Hakama et 
al, 2008; International Agency for Research on Cancer, 2005; Martin et al, 2007).  
However, cervical cancer prevalence rates are still increasing gradually, due to a 
combination of increased HPV transmission and changes in sexual lifestyles, 
especially among younger women (Nieminen et al, 2002, in International Agency 
for Research on Cancer, 2005).  Nevertheless, these organised screening 
programmes are based on cost-effectiveness and cost-minimisation analysis for 
each country, in order to ensure that resources are used most efficiently and 
projected at the target population, those for whom cervical cancer places the most 
burden (International Agency for Research on Cancer, 2005; Hakama, 1984, in 
Hakama et al, 2008).  Therefore, in accordance with HPV persistency and CIN 
progression rates, the underlying assumption in countries that commence 
screening around the age of 20, is that, for the majority of women, regular sexual 
intercourse begins between the ages of 16-18 (Sasieni and Castanon, 2006; 
Kitchener et al, 2006; Woodman et al, 2001, in Sasieni and Castanon, 2006).   
 
The argument against age-standardised screening programmes is that they ignore 
one’s individual risk for developing cervical cancer (unlike America and 
Australia) (Bano et al, 2008).  This too will be the case in Ireland; once 
CervicalCheck is in operation, all women aged under 25, who would like to be 
screened, will be discouraged from attending for cervical screening on the basis of 
their age, rather than being offered screening on the basis of their individual risk 
for developing cervical cancer (CervicalCheck, 2008; Castle et al, 2007; Barry et 
al, 2007).  Yet, considering that women under 25 present the third highest age-
specific incidence of preinvasive cervical cancer (CIN3) in Ireland and that the peak 
 22
incidence occurs between the ages of 25-29 (see Appendix B) (National Cancer 
Registry Ireland, 2006), arguments arise that,  
 
introducing Irish women to the cervical screening system before 
the age of 25 may be beneficial and may identify those at risk of 
developing later abnormalities (Keegan et al, 2007, p. 19), 
 
even if detected abnormalities are not treated until a later age.  Furthermore, 
commencing cervical screening from age 25 does not automatically mean that 
women will attend; attendance rates for organised screening programmes are 
approximately only 70% (International Agency for Research on Cancer, 2005), 
demonstrating that some women, who may be at high-risk for cervical 
abnormalities, may continue postponing screening, possibly due to a lack of 
knowledge about cervical cancer prevention (Bano et al, 2008).  Therefore, 
initiating screening before age 25 encourages women to become habitual about 
cervical screening and in combination with increased educational programmes, 
should help reduce any barriers, deterrents and erroneous knowledge to and of 
cervical cancer prevention (Sasieni and Castanon, 2006; Keegan et al, 2007; Bano 
et al, 2008).  
 
2.7 Summary  
This chapter examined the theoretical framework for cervical screening and 
demonstrated that cervical cancer is preventable in its preinvasive stage, through 
regular cervical screening and the early detection and treatment of precancerous 
lesions (International Agency for Research on Cancer, 2003, 2005).  The causal 
relationship between persistent HPV infection and cervical cancer was also 
examined, and the risk-factors for contracting HPV and developing cervical 
cancer were identified as being sexually active at a young age, having increasing 
numbers of sexual partners for females and their partners, having an STI, smoking 
and long-term oral contraceptive use (ibid).  It was also evident that the 
prevalence of these risk-factors is increasing among young women in Ireland 
(Layte et al, 2006).  In addition, the key barriers to the prevention of cervical 
cancer were examined and it was demonstrated that the majority of the barriers to 
cervical screening can be overcome through increased knowledge of the primary 
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and secondary prevention of cervical cancer, namely the HPV risk-factors and the 
importance of cervical screening (Walsh et al, 2003; Sabates and Feinstein, 2006).  
The age of screening initiation in various international cervical screening 
programmes was also considered in relation to international guidelines and best-
practice (International Agency for Research on Cancer, 2003, 2005).  Finally, the 
chapter concluded that, as women under 25 present the third highest incidence of 
preinvasive cervical cancer in Ireland (National Cancer Registry Ireland, 2006), 
cervical screening should be initiated before age 25, on the basis of one’s risk for 
developing cervical cancer, as ascertained from the abovementioned risk-factors 
(Keegan et al, 2007; Castle et al, 2007).   
 
This literature review provided the foundation for the present study to address the 
following research questions: 
4. What is the prevalence of the risk-factors for contracting HPV and 
developing cervical cancer among young women attending a third-level 
institute? 
5. Are there any links between the presence of these risk-factors, attendance 
for cervical screening and the young women’s abnormal cervical screening 
results?   
6. What are the key barriers to the prevention of cervical cancer among these 
young women? 
 
The following chapter examines the methodology used in the present study to 










3.1 Introduction  
The three core objectives of the present study are: to establish the prevalence of 
the HPV and cervical cancer risk-factors among young women attending a third-
level institute; to determine if any links exist between the presence of these risk-
factors, attendance for cervical screening and the abnormal results of these young 
women; and to ascertain these young women's key barriers to the prevention of 
cervical cancer.  The risk-factors were identified from literature as: being sexually 
active at a young age, having increasing numbers of sexual partners (LSP) for 
females and their partners, long-term oral contraceptive use, smoking and the 
occurrence of an STI.   
 
This chapter firstly describes the sampling framework and selection of 
participants and then justifies the chosen research methodology.  Next, the 
research instrument is comprehensively discussed and the ethical framework for 
the research is described.  The analysis of data is then concisely explained and 
lastly, a conclusion is drawn.    
 
3.2 Sample and Selection 
This study was based on a sample of 242 sexually active females aged 18-24 
attending a third-level institute in Ireland; the participants’ mean age was 21 
(Table 1 and Figure 1 below show the distribution of participants’ ages).  
Respondents’ inclusion in the sample was delineated by the following criteria: 
they had had sexual intercourse, they completed the survey and they were between 
the ages of 18-24, as CervicalCheck, the national cervical screening programme, 
advocates that women under 25 do not require cervical screening (CervicalCheck, 
2008).  Consequently, these inclusion criteria eliminated 166 of the 408 initial 
respondents, demonstrating a 59% inclusion rate. 
  
In addition, 41% (N=99) of participants were single; 30% (N=72) were in a short-
term relationship of less than 2 years; 26% (N=64) were in a long-term 
relationship of more than 2 years; and 3% (N=7) were in a long-term relationship 
and co-habiting.  
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A minimum target sample of 200 participants was set to ensure adequate 
representation of the target population, even though the precise number of young 
women attending the third-level institution could not be ascertained.  
 
Table 1: Participants’ ages (N=242) 
 
Mean Median RangeParticipants age 21 21 18-24 
 
 
































The sampling framework used to select respondents was internet sampling: after 
successfully piloting the survey, an internet link entitled ‘female sexual health 
survey,’ was posted on all student email accounts by a public relations officer 
associated with the third-level institute, inviting female students to visit a website 
to complete the survey (Sarantakos, 2005; Bryman, 2004).  Therefore, as all 
female students had a choice of partaking in the survey, the sample was 
constructed through self-selection (Sarantakos, 2005).  Furthermore, to encourage 
female students to participate in the survey, the link to the website was posted for 
four weeks during March and April, and pink-coloured information posters and 
leaflets (see Appendix K) were distributed around the institute’s campuses and in 
the ladies bathrooms.  However, as not all respondents were included in the study, 
the sample is a non-probability ‘purposive sample’, as inclusion was based on the 
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abovementioned criteria, namely respondents who were relevant to the study 
(Sarantakos, 2005; Denscombe, 2003).   
 
3.3 Research Methodology 
The choice of data collection was directly influenced by the abovementioned core 
objectives of this study.  Therefore, due to the sensitive nature of the subjective 
information required, a quantitative, self-completion, internet survey, designed by 
the researcher, was deemed most suitable in collecting this information, as this 
method focuses on objectivity and anonymity in the large-scale (Sarantakos, 
2005).  Furthermore, as there is no interaction between respondent and researcher, 
the anonymity afforded should have encouraged respondents to complete the 
survey honestly, thus helping to achieve representativeness of the specified 
population (ibid), whilst preventing social desirability occurring; “the tendency 
for respondents to distort answers in ways that will make them look better or will 
avoid making them look bad” (Fowler, 1995, p. 28).   
 
Additionally, the use of a quantitative survey allowed for the examination of 
relationships between independent and dependent variables “with the degree of 
accuracy that is required to establish social trends or to inform social policies” 
(Sarantakos, 2005, p. 45).  Independent variables, for example, the participant’s 
self-reported presence of the HPV and cervical cancer risk-factors and their 
knowledge of cervical cancer prevention are considered to influence dependent 
variables, which for the present study included the participant’s attendance for 
cervical screening and their abnormal cervical screening results (Bryman, 2008).  
As internet usage is particularly high among the sample group (Jones, 2002, as 
cited in Bryman, 2004), the internet survey also allowed greater representative 
access to the target population than would the distribution of questionnaires by 
hand (Bryman, 2004, 2008).  Moreover, internet surveys facilitate accurate 
responses to questions, resulting in less missing data, while their asynchronous 




3.4 Research Instrument  
The survey (see Appendix A) was divided into four sections containing a 
maximum of 42 questions: socio-demographic information (items 1-3 on age, 
relationship status and confirmation of attendance at the third-level institute), 
sexual history, cervical screening attendance and results, and barriers to cervical 
cancer prevention.  In consideration for the respondents, the survey was structured 
with the more intimate questions at the end so that respondents were not 
discomforted, while the survey was also designed to skip to the next appropriate 
question after each filter question (Bryman, 2004, 2008).  To garner greater depth 
of information, respondents were invited to elaborate upon their answers for 
several questions (ibid) and in addition, the majority of questions were structured 
to allow comparability with the risk-factors for developing cervical cancer as 
identified from literature (International Agency for Research on Cancer, 2003, 
2005).  
 
3.4.1 Prevalence of the HPV and Cervical Cancer Risk-factors 
Items 4-5 and 28-36 in the survey, addressed the prevalence of the risk-factors for 
contracting HPV and developing cervical cancer, including respondents age at 
sexual debut, their number of sexual partners (LSP), their partner’s LSP, their 
length of oral contraceptive use and their incidences of smoking and STIs 
(International Agency for Research on Cancer, 2003, 2005). 
 
3.4.2 Respondents’ Cervical Screening Attendance and Cervical Screening Results  
Items 15-21 and 23-24, contained 9 questions on respondents’ cervical smear test 
attendance and results, including the management of abnormal results and the age 
of screening initiation.  These questions allowed for comparability against the 
prevalence of the abovementioned risk-factors, while the latter question was 
included for comparability against international screening guidelines and best-





3.4.3 The Key Barriers to Cervical Cancer Prevention 
Items 25-26 focused on respondents’ personal (emotional) and practical 
(availability of screening) barriers to the secondary prevention of cervical cancer; 
cervical screening.  These items were structured so that comparability was 
possible with the barriers identified in the literature review, while respondents 
could also state barriers not included in the predetermined answers (Walsh, 2006; 
Walsh et al, 2003; Ni Riain et al, 2003; Irish Cancer Society, 2006).   
 
Items 6-14, 22 and 41-42, addressed respondents’ knowledge of the primary and 
secondary prevention of cervical cancer; namely, their knowledge of HPV and its 
risk-factors and their knowledge of the purpose of cervical screening and the 
meaning of a normal smear test result.  These questions intended to see if 
knowledge or lack thereof, was a barrier in the prevention of cervical cancer, and 
also allowed for comparison with the levels of knowledge identified in the 
literature review (Walsh, 2006; Walsh et al, 2003; Irish Cancer Society, 2006; 
International Agency for Research on Cancer, 2005; Philips et al, 2003).  
 
Finally, items 27 and 37-40, briefly examined respondents’ attitudes towards 
young women attending for cervical screening, paying for screening and HPV-
vaccination.  These items were measured using the Likert Scale and included as 
further possible barriers to the prevention of cervical cancer (Irish Cervical 
Screening Programme, 2004c, 2008a; Treanor et al, 2002; Keegan et al, 2007).  
 
3.5 Research Ethics 
The Economic and Social Research Council (2006) specify six principles of 
ethical research which sustain and encourage good ethical practice in social 
science research.  Whilst conducting the present study, these principles were 
addressed as follows: 
 
1. Research must ensure integrity and quality: the data was collected and 
downloaded into a database by a reputable, commercial research website, 
www.surveymonkey.com, and in addition to the quantitative design, this 
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allowed less chance for researcher bias intrusion or errors in the 
processing of data (Bryman, 2008).  
2. Participants must be fully informed of the research and their participation 
in the research: this was done via a detailed survey cover page (see 
Appendix A), whilst consent for participation was implied in the 
completion of the survey (Sarantakos, 2005).   
3. Confidentiality and anonymity of participants must be respected: no 
names, email addresses or any identifying characteristics were required 
from respondents and further guarantees of confidentiality and anonymity 
were detailed on the cover page (see Appendix A).  Additionally, direct 
comparisons were not made between participants in the study; this 
provided added confidentiality and anonymity (International 
Collaboration of Epidemiological Studies of Cervical Cancer, 2007). 
4. Participation must be voluntary: all female students in the third-level 
institute were invited to participate in the research and participation was 
on the basis of self-selection (Sarantakos, 2005).   
5. Harm to participants must be avoided: to ease any concerns that arose for 
respondents during the survey, they were automatically directed to the 
ICSP recommended website, www.tellher.ie, for further information on 
cervical screening and other related matters, when they exited or 
completed the survey.  Respondents were also protected from mental harm, 
as the survey could be completed at the respondent’s choice, whether 
online, emailed or posted to the researcher (see Appendix A) (Sarantakos, 
2005; Bryman, 2008). 
6. The researcher must be independent: the data was gathered through a 
self-completion internet survey, so as to protect the researcher’s 
neutrality and ensure that respondents were not influenced by the 
researcher (Sarantakos, 2005).  
 
The Declaration of Helsinki (World Medical Association, 2004) was also 
examined to ensure that the research was compliant with these ethical guidelines.  
 
 30
3.6 Data Analysis 
The data gathered for this research was analysed using the computer-based 
Statistical Package for Social Sciences (SPSS), version 15.  All closed-question 
variables were coded according to whether they were interval (the distance 
between the categories are equal, for example, participants’ age) or nominal (the 
categories cannot be rank ordered, for example, form of contraceptive) (Bryman, 
2004; Denscombe, 2003).  The relationships between these variables were 
determined using three statistical tests: the Chi-Square measured association 
between two nominal variables, the t-test between an interval and a nominal 
variable, and Pearson’s Correlation measured association between two interval 
variables (Bryman, 2004, 2008; Miller et al, 2002).   
 
3.7 Conclusion 
This chapter described the sample and selection of participants for the present 
study and justified the selection of an internet survey as the most appropriate data 
collection method of addressing the aforementioned core objectives of this 
research.  The research instrument in relation to the literature review was then 
explained, as was the ethical framework for the protection of research participants.  
Lastly, the analysis of the data was briefly described.   
 













4.1 Introduction  
This chapter presents the research findings from the present study and is divided 
into six chronological sections: the introduction, participants’ prevalence of the 
risk-factors for contracting HPV and developing cervical cancer, participants’ 
cervical screening attendance and cervical screening results, participants’ key 
barriers to the prevention of cervical cancer and lastly, a concise summary of the 
findings.       
 
The data is presented using tables and bar charts, and where possible, statistics are 
rounded off to the nearest whole percentage.  ‘Statistical association’ was 
obtained using the Chi-Square Test (χ2), t-test (t) or Pearson correlation (r) where 
appropriate; this asserts that the relationship between the variables are 
generalisable to the population the sample was drawn from (Bryman, 2004, 2008).  
Participants’ key encapsulating comments are also presented, followed by their 
age and where applicable, the letters CS indicate that they have attended for 


















4.2 Prevalence of HPV and Cervical Cancer Risk-Factors 
 
4.2.1 Participants’ Age at First Sexual Intercourse 
The mean age of sexual debut was 17.5 (see Table 2).  Figure 2 shows that 27% 
(N=66) of participants had sexual intercourse before age 17, which is considered a 
high risk for HPV infection.       
 
 
Table 2: Participants’ mean age at first sexual intercourse and mean number 
of sexual partners (N=242) 
 
 Mean Median Range
 Participants’ age at first sexual intercourse 17.5 17 14-22 




Figure 2: Distribution of participants’ ages at first sexual intercourse 
(N=242) 
   27%
(66) 
   63%
(153)













Participants age at first sexual intercourse
 
 
4.2.2 Participants’ Lifetime Number of Sexual Partners (LSP)  
Table 2 shows that participants’ mean LSP was 4.  Figure 3 shows that 69% 
(N=167) of participants reported at least 2 LSP, which increases the risk of 
contracting HPV.  
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Figure 3: Participants’ lifetime number of sexual partners (N=242) 
   31%
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1 LSP 2-3 LSP 4+ LSP
Participants lifetime number of sexual partners (LSP) 
4.2.3 Participants’ Partner’s Number of Sexual Partners (LSP)  
Table 3 shows that 31% (N=75) of participants seldom or never ask about their 
sexual partner’s sexual history.   
 
Table 3: Participants’ inclination to ask about their sexual partners sexual 
history (N=242) 
 
Inclination to ask Frequency % 
Always/Usually        116   48% 
  Sometimes   51   21% 
  Seldom/Never   75   31% 
Total  242 100%
 
 
55% (N=134) of participants knew their current (or last) sexual partner’s number 
of previous sexual partners (LSP); a mean of 3 (see Table 4).  Figure 4 shows that 




Table 4: Participants’ current (or last) sexual partner’s mean number of 
previous sexual partners (N=134) 
 
Mean Median RangeParticipants partner’s lifetime number of sexual 
partners 3 2 0-20 
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Figure 4: Participants’ current (or last) sexual partner’s number of previous 
sexual partners (N=134)  
   21%
(28)
   38%
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4.2.4 Participants’ Incidence of Sexually Transmitted Infections (STIs) 
Table 5 shows that 9% (N=21) of participants reported having had an STI, which 
increases the risk for HPV infection.   
 
 
Table 5: Participants’ incidence of STIs and smoking (N=242) 
 
 Yes No Don’t know Total 
Ever had an STI   9% (N=21) 76% (N=185) 15% (N=36) 100% (N=242)




4.2.5 Participants’ Incidence of Smoking  
Increasing exposure to smoking heightens one’s risk: Table 5 shows that 29% 
(N=71) of participants reported smoking, the mean number of cigarettes per week 
was 40 (see Table 6).   
 
Table 6: Participants’ mean incidence of smoking per week (N=71) 
 
Mean Median Range Participants who  




4.2.6 Participants’ Oral Contraceptive use  
62% (N=149) of participants reported use of the oral contraceptive pill (OCP), a 
risk-factor; 77% (N=114) of participants who reported OCP use also reported 
using male condoms.  Figure 5 shows firstly, the distribution of contraceptive use 
and secondly, the length of OCP use; 15% (N=22) of OCP users reported 5 or 
more years use, which further increases the risk of developing cervical cancer.  
 
 





























(* other forms of contraception included the Implant, Morning-after Pill, Depo-injection, Copper 
Coil and Nuva-Ring)  
 
 
4.2.7 Participants’ Simultaneous Incidence of the Sexual Behaviour Risk-Factors  
The prevalence of the sexual behaviour risk-factors were statistically examined to 
ascertain if they occurred simultaneously.   
  
Table 7 shows a significant relationship (r=-.386; p=0.001) between participants 
age at sexual debut and her number of sexual partners (LSP), indicating that the 
younger her age at sexual debut the greater her LSP.  Table 7 also shows a 
significant relationship (r=.316; p=0.001) between participants LSP and her 
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partner’s LSP; only 14% (N=19) of participants and their partners had a joint 




Table 7: Inter-correlation of sexual behaviour risk-factors  
 
 Participants age at sexual debut 
Participants number 
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* p<0.05          ** p<0.01          *** p<0.001 
 
 
Additionally, Figures 6 and 7 show that participants who reported an STI had a 
significantly (t=5.741; p=0.001; df=204) higher mean number of sexual partners 
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4.2.8 Summary of Results for the Presence of the Risk-Factors  
 
Table 8: Summary of results for the presence of the risk-factors (N=242)  
 
All women (N=242)Risk-factor N (%) 
Age at first intercourse  
▪ 17 and under   66 (27%) 
▪ 18 and over 176 (73%) 
Number of sexual partners  
▪ only 1   75 (31%) 
▪ 2 or more 167 (69%) 
Partners number of previous sexual partners (N=134)  
▪ none   28 (21%) 
▪ 1 or more 106 (79%) 
Sexually Transmitted Infection/Disease  
▪ yes 21 (9%) 
▪ no 221 (91%) 
Smoking  
▪ yes   71 (29%) 
▪ no 171 (71%) 
Oral Contraceptive Use  
▪ yes         149 (62%) 
▪ no   93 (38%) 
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4.3 Participants’ Cervical Screening Attendance Relative to the Presence of the 
Risk-Factors 
This section describes participants’ cervical screening attendance and then 
determines if attendance was associated with the presence of the aforementioned 
risk-factors.   
 
4.3.1 Participants’ Cervical Screening Attendance  
28% (N=68) of participants had attended for cervical screening.  A significant 
association was found (t=5.225; df=240; p=0.001) between screening attendance 
and participants current age; nevertheless, Figure 8 shows that just 33% (N=59) of 
all participants aged 20 or over have attended for screening.   
 
 





























Table 9 shows that participants’ mean age at first cervical screening was 19, the 
mean number of cervical smear tests was 2 and the mean screening interval time 
was just less than 2 years.  Figure 9 shows that 56% (N=38) of participants who 
attended for screening did so before age 20 (the minimum recommended 







Table 9: Mean age at, and number and interval of cervical smear tests (N=68) 
 
 Mean Median STD. Deviation 
Range 
 Age at first cervical smear test 19 19          1.7 16-24 
 Number of cervical smear 
tests 
 2  2  1.354 1-6 
 Cervical screening interval  1.8 years 




Figure 9: Participants’ age at first cervical smear test (N=68) 
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age 16-19 age 20+
 
 
Figure 10 shows that 51% (N=35) of participants attended their Family GP for 
cervical screening, while 31% (N=21) did not pay for screening; the approximate 
mean cost was €36.   
 
 



















  free   
(31%)(N=21)























(* other attendance included Maternity Hospital, Gynaecologist, Health-Board Clinic, Well 
Woman Centre and Family Planning Centre)  
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4.3.2 Participants’ Age at First Sexual Intercourse 
Figure 11 shows no statistical association (χ2=3.068; p=0.8; df=1) between 
cervical screening attendance and participants who made their sexual debut before 
age 17, which is considered a risk-factor; just 36% (N=24) of participants sexually 
active before age 17 have attended for screening. 
 
 
Figure 11: Participants’ cervical screening attendance and age at sexual 
debut (N=242) 
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Additionally, although a significant relationship was found demonstrating that 
initiation of cervical screening was linked with participants age at sexual debut 
(r=.466; p=0.001), Table 10 (using *) shows that 37% (N=25) of participants were 













Table 10: Participants’ age at sexual debut and initiation of cervical 
screening (N=68) 
 
Participants Age at Sexual Debut Age at First 
Screening 15 16 17 18 19 20 Total 
16    3 *    1 * 0 0 0 0 4 (6%) 
17 0    1 *    2 * 0 0 0 3 (4%) 
18 5 1    4 *    3 * 0 0 13 (19%)
19 0 4 5    7 *    2 * 0 18 (27%)
20 2 6 3 3    1 * 0 15 (22%)
21 0 1 1 3 2    1 *  8 (12%) 
22 0 0 1 1 3 0 5 (7%) 




















4.3.3 Participants’ Lifetime Number of Sexual Partners (LSP) 
Figure 12 shows that participants who reported 2 or more LSP, a risk-factor, had a 
statistically higher (χ2=9.706; p=0.002; df=1) screening attendance than 
participants reporting 1 LSP.    
 
 
Figure 12: Participants’ cervical smear test attendance and number of sexual 
partners (N=242)  
 




























4.3.4 Participants’ Partner’s Number of Sexual Partners (LSP)  
Figure 13 shows no statistical association (χ2=0.23; p=0.879; df=1) between 
cervical screening attendance and participants whose partner reported more than 1 
previous LSP, a risk-factor.  
 
 
Figure 13: Participants’ cervical smear test attendance by their partner’s 
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4.3.5 Participants’ Incidence of Sexually Transmitted Infections (STIs)  
Figure 14 shows a significantly (χ2=13.007; p=0.001; df=1) higher cervical 
screening attendance for participants who reported an STI, a risk-factor.    
  
 
Figure 14: Participants’ cervical smear test attendance and their incidence of 
sexually transmitted infections (N=242)  
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4.3.6 Participants’ Incidence of Smoking  
Figure 15 shows no significant association (χ2=2.516; p=0.113; df=1) between 
screening attendance and participants who reported smoking, a risk-factor.  
 
 
Figure 15: Participants’ cervical smear test attendance and their incidence of 
smoking (N=242)  
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4.3.7 Participants’ Oral Contraceptive Pill (OCP) use  
Although no statistical association (χ2=3.252; p=0.71; df=1) was found between 
cervical screening attendance and participants who reported OCP use, a risk-
factor, Figure 16 shows a significant link (χ2=7.376; p=0.025; df=2) between 
screening attendance and increasing duration of OCP use.   
 
 
  Figure 16: Participants’ cervical smear test attendance in relation to 
increasing duration of oral contraceptive pill use (N=149)  
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4.3.8 Summary of Results of Statistical Tests for Cervical Screening Attendance  
 
Table 11: Attendance for cervical screening relative to the presence of the 
risk-factors (N=242)  
 
Cervical Screening  Risk-factor Yes (N=68) No (N=174) 
Statistical 
Association 
Age at first intercourse    
▪ 17 and under (N=66) 24 (36%)   42 (64%) 
▪ 18 and over (N=176) 44 (25%) 132 (75%) 
None (χ2=3.068; 
p=0.80; df=1) 
Number of sexual partners    
▪ only 1 (N=75) 11 (15%)   64 (85%) 
▪ 2 or more (N=167) 57 (34%) 110 (66%) 
χ2=9.706; 
p=0.002; df=1 
Partners number of previous 
sexual partners (N=134)  
  
▪ none (N=28)   7 (25%)    21 (75%) 
▪ 1 or more (N=106) 28 (26%) 78 (74%) 
None (χ2=0.23; 
p=0.879; df=1) 
Sexually Transmitted Infection    
▪ yes (N=21) 13 (62%)     8 (38%) 
▪ no (N=221) 55 (25%) 166 (75%) 
χ2=13.007; 
p=0.001; df=1 
Smoking    
▪ yes (N=71) 25 (35%)   46 (65%) 
▪ no (N=171) 43 (25%) 128 (75%) 
None (χ2=2.516; 
p=0.113; df=1) 
Oral Contraceptive Use (N=149)    
▪ 4 years or less use (N=127) 37 (29%) 90 (71%) 




4.4 Participants’ Cervical Screening Results Relative to the Presence of the Risk-
Factors 
Participants’ cervical screening results were statistically examined for association 
between abnormal results and the abovementioned risk-factors.  
 
4.4.1 Participants’ Cervical Screening Results  
93% (N=63) of participants who had attended for cervical screening knew their 
screening results; 64% (N=40) were normal and 36% (N=23) reported 
abnormalities, including 7 cases of preinvasive cervical cancer, CIN2/3 (see Table 
12).  Additionally, all participants reporting CIN2/3 (11%) attended for 6 monthly 
or annual screening. 
 
Table 12: Distribution of participants known cervical smear test results 
(N=63) 
 
Cervical Smear Test Results Frequency % 
Normal  40   64% 
Borderline Abnormalities/Changes (BNA)  12   19% 
CIN 1   4     6% 
CIN 2   4     6% 
CIN 3   3     5% 
Total 63 100% 
 
 
Figure 17 shows a trend between the grade of abnormal screening results and 
attending for colposcopy/biopsy; 65% (N=15) of abnormal results received further 
investigation.  
 
































4.4.2 Participants’ Age at First Sexual Intercourse  
Figure 18 shows a statistical association (χ2=6.260; p=0.012; df=1) between 
abnormal results and participants who made their sexual debut before age 17, a 
risk-factor.   
 
 
Figure 18: Participants’ age at sexual debut and their cervical screening 
results (N=63) 
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4.4.3 Participants’ Lifetime Number of Sexual Partners (LSP)  
Figure 19 shows a statistical association (χ2=6.835; p=0.009; df=1) between 
abnormal cervical screening results and participants who reported 2 or more LSP, 
a risk-factor.  
 
Figure 19: Participants’ lifetime number of sexual partners and their cervical 
screening results (N=63) 
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4.4.4 Participants’ Partner’s Number of Sexual Partners (LSP)  
Figure 20 shows that no statistical association could be ascertained between 
abnormal screening results and participants whose partner reported more than 1 
previous LSP, a risk-factor, as only 43% (N=10) of participants who reported 
cervical abnormalities knew their partner’s LSP.  
 
 
Figure 20: Participants’ cervical screening results and their partner’s 
number of sexual partners (N=33) 
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4.4.5 Participants’ Incidence of Sexually Transmitted Infections (STIs)  
Figure 21 shows no statistical association (χ2=0.657; p=0.417; df=1) between 
abnormal screening results and participants’ who reported ever having an STI.   
 
 
Figure 21: Participants’ cervical screening results and their incidence of 



















4.4.6 Participants’ Incidence of Smoking  
Figures 22 and 23 show no statistical association between abnormal cervical 
screening results and firstly, participants who reported smoking (χ2=0.445; 
p=0.505; df=1) and secondly, their number of cigarettes smoked per week 
(t=0.830; p=0.401; df=22).   
 
 
Figure 22: Participants’ cervical screening results and their incidence of 
smoking (N=63) 
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Figure 23: Participants’ cervical screening results and their mean number of 
cigarettes smoked per week (N=63) 
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4.4.7 Participants’ Oral Contraceptive Pill (OCP) use 
Although Figure 24 shows no statistical association (χ2=2.140; p=0.143; df=1) 
between abnormal screening results and increasing duration of OCP use, half the 
participants who reported long-term OCP use, also reported cervical 
abnormalities.  
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Figure 24: Participants’ cervical screening results and length of oral 
contraceptive pill use (N=45) 
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4.4.8 Summary of Results of Statistical Tests for Cervical Screening Results  
 
Table 13: Cervical screening results, relative to the presence of the risk-
factors (N=63)  







Age at first intercourse    
▪ 17 and under (N=23) 10 (43%) 13 (57%) 
▪ 18 and over (N=40) 30 (75%) 10 (25%) 
χ2=6.260; 
p=0.012; df=1 
Number of sexual partners    
▪ only 1 (N=10)  10 (100%)     0 
▪ 2 or more (N=53)     30 (57%) 23 (43%) 
χ2=6.835; 
p=0.009; df=1 
Partner’s number of previous 
sexual partners (N=33)  
  
▪ none (N=6)       5 (84%) 1 (16%) 
▪ 1 or more (N=27) 18 (67%) 9 (33%) 
None (χ2=0.646; 
p=0.422; df=1) 
Sexually Transmitted Infection    
▪ yes (N=13)       7 (54%)      6 (46%) 
▪ no (N=50) 33 (66%) 17 (34%) 
None (χ2=0.657; 
p=0.417; df=1) 
Smoking    
▪ yes (N=24) 14 (58%) 10 (42%) 
▪ no (N=39) 26 (67%) 13 (33%) 
None (χ2=0.445; 
p=0.505; df=1), 
Oral Contraceptive Use (N=45)    
▪ 4 years or less use (N=35) 26 (74%)  9 (26%) 





4.5 Participants’ Key Barriers to Cervical Cancer Prevention  
This section identifies participants’ key barriers to the prevention of cervical 
cancer. 
 
4.5.1 Participants’ Knowledge of Cervical Cancer Prevention 
Figure 25 shows that participants’ perceived sufficient knowledge of cervical 
cancer, the secondary prevention of cervical cancer (cervical screening) and the 
primary cause of cervical cancer (HPV), was considerably low.  Nevertheless, an 
association was found between participants’ attendance for cervical screening and 
participants’ perceived sufficient knowledge of cervical cancer (χ2=8.487; 
p=0.004; df=1) and cervical smear tests (χ2=29.916; p=0.001; df=1). 
 
 
 Figure 25: Participants’ perceived sufficient knowledge of cervical cancer, 
cervical screening and HPV (N=242) 
Do you feel you know enough about...
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Table 14 shows that 72% (N=174) of participants correctly identified that the 
purpose of a cervical smear test is to ‘detect changes in the cells of the cervix’, 
while Table 15 shows that 72% (N=175) of participants correctly identified that a 
normal cervical smear test means ‘a low risk of developing cervical cancer’.  
However, Figure 26 shows that of participants who had attended for cervical 
screening, 16% (N=11) did not correctly identify the purpose of a cervical smear 
test, while 21% (N=14) did not identify the meaning of a normal result.        
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Table 14: Knowledge of the purpose of a cervical smear test (N=242) 
 
The purpose of a cervical smear test is to ….. Frequency % 
     Detect changes in the cells of the cervix 174   72% 
     Detect cervical cancer   33   13% 
     Detect STIs/infection   26   11% 
     Don’t know     9     4% 




Table 15: Knowledge of the meaning of a normal cervical smear test result 
(N=242) 
A normal cervical smear test result means a …. Frequency %  
     Low risk of developing cervical cancer  175   72% 
     No risk of developing cervical cancer    19     8% 
     Don’t know   48   20% 




Figure 26: Knowledge of participants who had attended for cervical 
screening (N=68) 
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Furthermore, although 34% (N=82) of participants reported awareness of HPV 
prior to this research, when asked to list the risk-factors for contracting HPV, 
Table 16 shows that 47% (N=115) said they did not know and 26% (N=62) stated 
they had never heard of HPV (the correct risk-factors identified are marked ‘●’).  
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Nevertheless, a significant association (χ2=7.327; p=0.007; df=1) was found 
between cervical screening attendance and awareness of HPV.  
 
 
Table 16: Knowledge of the risk-factors for contracting HPV (N=242) 
 
Risk Factor for contracting HPV Frequency % Reported
     Don’t know 115 47% 
     Never heard of HPV   62 26% 
     Having (unprotected) sex ●   65 27% 
     Having many sexual partners ●   10   4% 
     Being sexually active at a young age ●     2   1% 
     Other: smoking, cervical cancer, family history   28 11% 




Additionally, participants’ abovementioned lack of knowledge about cervical 
cancer prevention was apparent in their qualitative comments: 
• “This form of cancer I know very little about in comparison to others, for 
example Breast Cancer” (Participant 395, age 23).  
• “I have a vague idea about smear tests, but don’t understand in detail for 
example when they are necessary and what exactly takes place” 
(Participant 344, age 19).  
• “I just know that most people my age get them to check for STIs” 
(Participant 266, age 21, CS).  
• “I thought it was only when women have unprotected sex that they need to 
have a smear test” (Participant 367, age 19).  
• “There definitely needs to be better awareness of the HPV virus as a cause 
of cervical cancer.  I was not aware that it even existed until I visited my 






4.5.2 Participants’ Reception of Sex Education in School  
78.5% (N=190) of participants received sex education in school; Figure 27 shows 
that information on cervical screening, cervical cancer and HPV was seldom 
included.   
 
• “The only sexual health education I’ve received in school has been from a 
religious standpoint advocating abstinence and giving very little attention 
to actual physical health” (Participant 122, age 21).  
 
No association was found between reception of sex education and attendance for 
cervical screening (χ2=0.692; p=0.406; df=1), or perceived knowledge of cervical 
cancer (χ2=0.010; p=0.921; df=1), cervical screening (χ2=0.232; p=0.630; df=1) or 
HPV (χ2=0.544; p=0.462; df=1).   
 
Figure 27: Information included in sex education (N=190) 
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4.5.3 Participants’ Attitudes  
Figure 28 presents participants’ attitudes as possible barriers to cervical cancer 
prevention; however, no association was found between attendance for cervical 
screening and attitudes towards screening women under 25 (χ2=3.535; p=0.60; 
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df=1), paying for cervical screening (χ2=0.009; p=0.923; df=1), HPV-vaccination 
(χ2=1.860; p=0.173; df=1) or free cervical screening (χ2=0.001; p=0.977; df=1).   
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Participants’ qualitative comments regarding these attitudes included: 
• “As a student I would definitely be more likely to take cost into account.  
It’s easy to know you shouldn’t, but immediate concerns take priority.  
Young people are the most easily receptive to being educated about this 
stuff, so if testing were free in conjunction with that, it might be very easy 
to form good habits” (Participant 065, age 20, CS).  
• “Having it as a free service will make attendance more common and 
therefore take embarrassment out of it” (Participant 157, age 24, CS).  
• “I think women are more sexually active younger and younger and 
therefore the lower age limit for a smear should be lowered” (Participant 
052, age 21). 
• “The risk is too low to be feasible [screening women under 25], but it 
should depend on sexual activity and the age you begin to be sexually 
active” (Participant 290, age 21). 
• “I am under 25 and have already had colposcopy and LLETZ.  I was 
relived to have had the test done and been treated so early on.  Under 25s 
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are still at risk from cell changes which could result in cervical cancer if 
undetected” (Participant 314, age 24, CS, CIN3).  
• “Any preventative measure against the development of cancer is great in 
my eyes.  I think however, that it is the decision of the girl and her parents 
following adequate education of the risks of HPV” (Participant 067, age 
22, CS).  
 
4.5.4 Participants’ Personal and Practical Barriers to Cervical Screening 
Attendance 
The abovementioned lack of knowledge about the prevention of cervical cancer 
was also evident in the personal (emotional) and practical (availability of 
screening) barriers to cervical screening attendance, as reported by participants 
who had not attended for cervical screening (N=174; 72%).   
 
 
Table 17: Personal barriers to cervical screening (N=174) 
 
Personal Barriers Frequency % Reported
     Don’t think I need a cervical smear test/never told  
     to have one   101    58% 
     Embarrassment    46    26% 
     Fear of cervical screening/what might be found    56    32% 
     Don’t know where to go for cervical screening     30    17% 
     Concerns about having a male smeartaker    28    16% 
     Told not to have a smear test until age 25+    27    16% 
     Don’t know what cervical smear tests are for   16     9% 
     Don’t know at what age to have a cervical smear   
     test        13     7% 




Table 18: Practical barriers to cervical screening (N=174) 
 
Practical Barriers Frequency % Reported 
     Lack of time   50    29% 
     Too expensive   33         19% 
     Fears about confidentiality    15     9% 
     Unsuitable appointment times   15     9% 
     No practical barrier stated   80   46% 
     Total responses 193 100% 
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These barriers were also highlighted in participants’ qualitative comments:   
• “My doctor told me I don’t need one till I'm 25, even though I’d like one 
done and then a nurse told me I should get one done ASAP cos I'm with my 
boyfriend and on the pill 5 years” (Participant 87, age 21).  
• “It’s not something iv thought about.  I suppose I presume when I need to 
get one (for example depending on age) I’d hear through friends or 
whatever” (Participant 158, age 20).  
• “I have attempted to go for a smear test in the past but I get too frightened 
and nervous that I am never able to go through with it” (Participant 240, 
age 22). 
 
(See Appendix L for all qualitative comments made by participants). 
 
4.6 Summary of Key Findings 
This chapter presented the findings from an internet survey completed by 242 
sexually active young women attending a third-level institute.  Findings on the 
prevalence of the risk-factors for contracting HPV and developing cervical cancer 
were presented and statistical associations were found between the sexual 
behaviour risk-factors; namely, being sexually active at a young age, having 
multiple sexual partners and reporting an STI.  The findings also demonstrated 
statistical associations between cervical screening attendance and the presence of 
3 risk-factors: 2 or more sexual partners, an STI and increasing duration of OCP 
use.  Statistical associations were also found between abnormal cervical screening 
results and being sexually active before age 17 and having 2 or more sexual 
partners; over one-third of cervical screenings reported abnormalities.  Finally, the 
key barriers to the prevention of cervical cancer, indicated a lack of sufficient 
knowledge about cervical cancer, the secondary prevention of cervical cancer 
(cervical screening) and the primary cause of cervical cancer (HPV).  
 




5.1 Introduction  
This chapter discusses the research findings, presented in Chapter Four, in relation 
to the aims of this research, the foundation for which was outlined in the literature 
review in Chapter Two.  This chapter begins by examining the prevalence of the 
risk-factors among the sample group, namely being sexually active at a young 
age, females and their partners having increasing numbers of sexual partners 
(LSP), having an STI, smoking and long-term oral contraceptive use 
(International Agency for Research on Cancer, 2003, 2005).  The cervical 
screening attendance of participants is then compared against these risk-factors 
and against best-practice and international guidelines (ibid), followed by a 
discussion of participants’ cervical screening results in relation to the risk-factors 
and recent research.  Afterwards, participants’ key barriers to the prevention of 
cervical cancer, specifically their knowledge of the primary and secondary 
prevention of cervical cancer are examined and lastly, a summary is drawn. 
 
5.2 Discussion of Findings  
5.2.1 Prevalence of HPV and Cervical Cancer Risk-Factors 
The findings from the present study suggest that the prevalence of the risk-factors, 
especially the sexual behaviour risk-factors, may be increasing.  The mean age for 
sexual debut in the present study was 17.5, with over one-quarter of participants 
reporting sexual intercourse before the legal age of 17 in Ireland (Rundle et al, 
2008).  Furthermore, over two-thirds of participants reported at least two sexual 
partners (LSP) (the mean was four) and considering the present study’s findings 
that the younger the participant at sexual debut, the higher her number of LSP 
tended to be, this suggests that a substantial proportion of the participants may 
have been exposed to HPV for lengthy periods (Bosch et al, 2002; Todd and 
Shafi, 2004).  Additionally, as the findings from the present study demonstrated 
that the more LSP reported by participants, the more LSP her partner was inclined 
to report, the tenfold increase in the transmission and infection rate of HPV 
among young people in Ireland is comprehensible, especially as less than one-
sixth of participants in the present study reported a joint history with their partner 
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of no previous LSP (National Disease Surveillance Centre, 2001, in Comber and 
Gavin, 2004; Health Protection Surveillance, 2008b).   
 
The findings from the present study that one-third of participants seldom or never 
ask about their partners sexual history, is worrisome in light of the fact that the 
lack of such knowledge is associated with increased HPV infection (Moscicki, 
2005; Winer et al, 2003).  Moreover, findings from the present study that one-
tenth of participants reported an STI while one-sixth did not know if they had an 
STI, may be indicative of this lack of knowledge and corresponds to the present 
study’s findings that having an STI is associated with increasing numbers of LSP 
and a younger age at sexual debut.  These findings are comparable to the 
demographically representative ‘Irish Study of Sexual Health and Relationships’ 
(ISSHR) (Layte et al, 2006) and suggests that the prevalence of the sexual 
behaviour risk-factors for contracting HPV may be increasing among young 
women.  This is also consistent with the fact that HPV is the most commonly 
reported STI among young people in Ireland; unaided, several participants in the 
present study stated they were HPV-positive (see Appendix L) (Gilson and 
Mindel, 2001; Health Protection Surveillance Centre, 2008b).   
 
Over one-quarter of participants in the present study reported smoking and 
although the reported mean of 40 cigarettes per week was below the significant 
level of 120, this still suggests that if participants were to contract HPV, they may 
not be able to clear the infection as easily and may have a greater risk of 
progressing to a higher grade of CIN and of CIN treatment failure (Shafi and 
Welton, 2007).  Moreover, the incidence of oral contraceptive pill (OCP) usage by 
approximately two-thirds of participants in the present study, one-sixth of whom 
reported more than five years use, in-conjunction with abovementioned 
prevalence of the sexual behaviour risk-factors, suggests not only a greater risk of 
HPV persistency within the sample group, but also a higher prevalence of the co-
factors that influence the progression from HPV infection to preinvasive cervical 
cancer (International Agency for Research on Cancer, 2003; Leeson, 2005; Harper 
and Paavonen, 2008).   
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5.2.2 Cervical Screening Attendance 
The findings from the present study demonstrated that less than one-third of 
participants had attended for cervical screening, which was comparable to 
research (Irish Cancer Society, 2006).  The present study also demonstrated, 
encouragingly, that participants were more inclined to attend for cervical 
screening if the abovementioned sexual behaviour risk-factors were present.  
However, it appears that the minimum time-frame needed for HPV to establish 
persistency may not have been consistently followed in relation to these risk-
factors (Kitchener et al, 2006).  For example, the findings from the present study 
indicated that of participants who had attended for cervical screening, over one-
third did so within a year of sexual debut, while over half did so before the 
minimum recommended screening age of 20 (European Commission, 2003, in 
Sasieni and Castanon, 2006).  These statistics suggest that these young women 
were screened needlessly, as a HPV infection will not have had time to establish 
persistency or to spontaneously clear itself within a year; consequently, inaccurate 
cervical screening results are possible (Martin et al, 2007; Kitchener et al, 2006).  
Moreover, although the likelihood is low that cervical abnormalities detected in 
women under 20 will progress to cervical cancer (Sasieni and Castanon, 2006), all 
abnormal screening results must follow management protocols until negative 
results are acknowledged (see Appendix F), with the possibility that meanwhile 
these young women may experience avoidable psychological distress (Karasz et 
al, 2003, in Chew-Graham et al, 2006). 
 
Conversely, the findings from the present study that approximately only one-third 
of participants sexually active before age 17 and one-third of participants aged 20 
and over have attended for screening, suggests two possibilities: firstly, the 
minimum age for screening and the risk-factors for contracting HPV were not 
present so cervical screening was uncalled-for, or secondly, participants were not 
offered or were refused cervical screening, regardless of the risk-factors, as they 
were not aged 25 (Castle et al, 2007; International Agency for Research on 
Cancer, 2005; Ni Riain et al, 2003).  The present study also indicated that 
although an increasing duration of OCP use improved the likelihood of cervical 
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screening attendance, presumably due to increased cytological surveillance 
(Bosch et al, 2002), the presence of the co-factors alone, OCP use and smoking, 
had no association with cervical screening attendance.  This suggests that the 
sexual behaviour risk-factors were not present and so cervical screening was 
unwarranted, or the influence these co-factors have on the HPV-dependent 
pathway of carcinogenesis was not thoroughly contemplated when examining the 
need for cervical screening (International Collaboration of Epidemiological 
Studies of Cervical Cancer, 2007; International Agency for Research on Cancer, 
2003).   
 
5.2.3 Cervical Screening Results 
In relation to the initiation of cervical screening, Ireland advocates that screening 
women aged under 25 is not necessary (Ni Riain et al, 2003), yet the findings 
from the present study demonstrated that over one-third of cervical screening 
results were abnormal, including one-tenth CIN2/3 (preinvasive cervical cancer).  
These results are considerably higher than the estimation that less than one-tenth 
of smears are abnormal (ibid) and remains so, even when the one-third of lesions 
that are expected to spontaneously regress, are deducted from the results (Hakama 
et al, 2008; International Agency for Research on Cancer, 2003).  Two 
possibilities may account for this heightened incidence of cervical abnormality 
within the present study: firstly, a percentage of these abnormal results may 
actually be inaccurate results, due to the aforementioned high proportion of 
cervical smear tests performed on participants aged under 20 and within a year of 
sexual debut (Stoler and Schiffman, 2001, in Myers et al, 2008) or secondly, the 
association between abnormal screening results and the strength of the risk-factors 
for contracting HPV, specifically being sexually active before age 17 and having 
increasing LSP, suggests that the duration and amount of exposure to HPV has 
determined the probability that some of the young women who participated in the 
present study may have been infected with HPV (Deacon et al, 2000).    
 
Furthermore, the finding from the present study that the woman’s partner’s LSP 
has no association with abnormal cervical screening results, suggests that an 
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increased risk of cervical abnormalities and HPV infection may be more strongly 
associated with sexual intercourse with a new partner, than with the one partner 
who has reported many LSP (Winer et al, 2003; Deacon et al, 2000).  
Alternatively, the present study’s findings that less than half of participants who 
reported cervical abnormalities knew their partner’s LSP, supports the concept 
that a lack of knowledge about a partner’s sexual history is associated with HPV 
infection (Moscicki, 2005; Winer et al, 2003).  The present study also showed no 
association between long-term OCP use and abnormal screening results, which 
suggests that long-term OCP use itself may not strictly be a potential cervical 
cancer risk-factor; conversely, this finding may be attributed to the high 
prevalence of combined OCP and male condoms usage in the present study, 
which may have protected participants from contracting HPV (International 
Collaboration of Epidemiological Studies of Cervical Cancer, 2007; Sasieni, 
2007).  A lack of association with abnormal results was also found between 
participants’ incidence of smoking and their STI status; however, as the present 
study was only an immediate snap-shot of cervical screening attendance and 
results, it is possible that an extended study would highlight long-term 
associations between the presence of these co-factors and the progression of 
oncogenic HPV infection and/or CIN grades (Shafi and Welton, 2007; Bosch et 
al, 2002).  
 
Nevertheless, the present study found that the management of abnormal cervical 
screening results was in accordance with protocol (see Appendix F), as all 
participants reporting CIN2/3 (preinvasive cervical cancer) had attended for 
colposcopy/biopsy and also attended for screening at six monthly or annual 
intervals.  Furthermore, the findings from the present study that only one-third of 
participants reporting CIN2/3 had undergone LLETZ, in-conjunction with the 
findings that some participants had attended for six cervical smear tests, suggests 
that smeartakers favour monitoring the progression of CIN2/3 rather than 
employing ablative procedures (Keegan et al, 2007).  However, considering that 
Ireland does not advocate screening women under 25, even if the young women in 
the present study had attended for cervical screening from age 20 based on the 
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presence of the risk-factors, attending for six cervical screenings is still a higher 
screening rate than the yearly screening advocated for this age group by American 
cervical screening guidelines and may have caused the young women distress 
(American Cancer Society, 2007, in Myers et al, 2008; International Agency for 
Research on Cancer, 2003, 2005).  Additionally, although the mean cervical 
screening interval of two years found in the present study was more frequent than 
the 3-5 years advocated in Ireland, the considerably higher presence of cervical 
abnormalities and the consequence of their management (more frequent 
screening) may account for this finding (International Agency for Research on 
Cancer, 2003, 2005).  Moreover, the present study found that just under one-tenth 
of participants who had attended for screening, did not know their results; this 
suggests that they are either awaiting their results or were not informed of them, 
through their own lack of follow-up or that of their smeartakers (Kahn et al, 
2001).   
 
The finding from the present study that seven participants reported preinvasive 
cervical cancer screening results, indicates a CIN3 (N=3) incidence rate of 47.6 
per 1,000 women aged 18-24, which is remarkably higher than the 1.72 reported 
(see Appendix B) (National Cancer Registry Ireland, 2006).  When considered 
that the highest incidence of preinvasive cervical cancer occurs in the 25-29 age 
cohort (see Appendix B) (ibid), this suggests that the initiation of cervical 
screening should begin prior to age 25, firstly, to detect cervical abnormalities that 
would otherwise not be detected until after age 25 and then possibly at a higher 
CIN grade and secondly, to reduce the burden of preinvasive cervical cancer 
among the 25-29 age group (Keegan et al, 2007).   
 
5.2.4 The Key Barriers to the Prevention of Cervical Cancer  
The present study demonstrated that participants had a low level of perceived 
sufficient knowledge, that is, participants felt they did not know enough, about 
cervical cancer, cervical screening and HPV, which is consistent with Irish 
research (Cotter et al, 1999, in Martin et al, 2007; Alder and Foxwell, 1999, in 
Walsh, 2006).  This lack of knowledge was evident as just under three-quarters of 
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participants in the present study correctly stated that the purpose of a smear test 
was to detect changes in the cells of the cervix, whilst the same proportion of 
participants correctly identified that a normal cervical smear test result meant a 
low risk of developing cervical cancer; this is similar to other research (Walsh et 
al, 2003; Walsh, 2006).  Moreover, although the present study demonstrated that 
sufficient knowledge of cervical cancer and cervical screening was statistically 
associated with cervical screening attendance, approximately one-fifth of 
participants who had attended for cervical screening in the present study did not 
correctly identify the purpose of cervical screening or the meaning of a normal 
smear test result.  This suggests that the additional role of smeartakers as 
educators was not adequately exercised, as every women who attends for cervical 
screening must be informed, accurately, of the processes and consequences of 
screening, including knowing the purpose of cervical screening and the meaning 
of a normal/abnormal result (Ni Riain et al, 2003; Stark et al, 2008; International 
Agency for Research on Cancer, 2005).  In addition, the inaccurate association 
made by one-tenth of participants in the present study that cervical screening 
detects STIs, supports the above insinuation and indicates that some participants 
may have attended for cervical screening in the belief that it was an STI test.  
 
In relation to knowledge about HPV, one-third of participants in the present study 
reported awareness of HPV prior to the research, which was statistically related to 
cervical screening attendance.  Yet, awareness of HPV does not necessarily imply 
knowledge, as was evident when participants in the present study were asked to 
list the risk-factors for contracting HPV; only one-quarter of the participants 
correctly identified that the risk-factors are linked to sexual behaviour, whilst half 
said they did not know and one-quarter stated they had never heard of HPV.  
These findings suggest that although ano-genital warts/HPV is the most 
commonly reported STI among young people in Ireland, the lack of knowledge 
about the transmission of HPV may have contributed to its high prevalence and 
may also be indicative of the high proportion of abnormal screening results found 
in the present study (Health Protection Surveillance, 2008b).  Moreover, this 
observed low knowledge about the high risk for contracting HPV, in-conjunction 
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with the demonstrated lack of knowledge about cervical screening, additionally 
suggests a poor communicative relationship between healthcare-providers and the 
participants in the present study, regarding the primary and secondary prevention 
of cervical cancer (Frega et al, 2003; Sabates and Feinstein, 2006; Kahn et al, 
2001).   
 
The findings from the present study that General Practitioners were the primary 
location for cervical screening attendance, suggests that they were also the main 
providers of information, and considering that knowledge of cervical cancer 
prevention tended to be statistically higher among participants in the present study 
who had attended for screening, this suggests that young women’s knowledge 
about cervical cancer prevention was not being adequately addressed, prior to the 
initiation of screening and within school-based sex education (Rundle et al, 2008).  
The present study found that whilst more than three-quarters of participants had 
received sex education in school, information on cervical cancer, cervical 
screening and HPV was seldom included, demonstrating the discretion afforded to 
schools regarding the content of their sex education curriculum (Hyde and 
Howlett, 2004; Department of Education, 1997).  Furthermore, the present study 
demonstrated that nearly one-quarter of participants had received no formal sex 
education, which is higher than estimated (Rundle et al, 2008) and may have 
exaggerated participants’ lack of knowledge and communication about cervical 
cancer prevention (Sabates and Feinstein, 2006).  Additionally, the findings from 
the present study that reception of sex education tended to have no influence on 
participants’ knowledge of the primary and secondary prevention of cervical 
cancer, indicates the limitations of sex education in providing a comprehensive 
understanding of physical health within sexuality and relationships (Cousins et al, 
2008; Martin et al, 2007; Irish Cancer Society, 2006).  Consequently, this was 
also likely to exasperate the barriers to the initiation of screening (World Health 
Organisation, 2005, in Sasieni and Castanon, 2006).      
 
In the present study, the participants’ personal and practical barriers to the 
initiation of cervical screening, were consistent with research and tended to 
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reiterate their lack of knowledge and communication about cervical cancer 
prevention as discussed above, for example: ‘don’t know what cervical smear 
tests are for’, ‘concerns about having a male smeartaker’ and ‘fear of cervical 
screening/what might be found’ (Kahn et al, 2001; Walsh et al, 2003; Walsh, 
2006).  Additionally, barriers reported in the present study, including ‘don’t think 
I need a cervical smear test’, ‘told not to have a cervical smear test until I am age 
25+’, ‘don’t know at what age to have a cervical smear test’ and ‘lack of time’, 
suggest firstly, a lack of knowledge and communication between participants and 
their healthcare-provider about the risk-factors associated with cervical cancer and 
the importance of cervical screening and suggests secondly, that some participants 
may have been refused screening (Irish Cancer, Society, 2006; Sabates and 
Feinstein, 2006; Fylan, 1998).  Yet, considering the high proportion of cervical 
smear tests carried out on women under 20 in the present study, these barriers 
imply that smeartakers and participants were unsure about the initiation of 
screening in women outside the eligible aged 25-60 population (CervicalCheck, 
2008).  Consequently, these barriers also suggest that within the present study, 
smeartakers were firstly not respecting patient autonomy in decision-making 
about attending for screening, possibly because of participants’ abovementioned 
lack of knowledge and communication regarding cervical cancer prevention, and 
secondly, smeartakers were not exercising their ethical responsibility to provide 
screening to those who are most in need of it, by thoroughly reviewing their 
sexual and behavioural history (International Agency for Research on Cancer, 
2005; Irwig et al, 2006). 
 
Although the participants in the present study generally stated that paying for 
cervical screening was a barrier and that cervical screening should be free of 
charge to all women, the present study showed that the third-level institute’s 
health centre was the least expensive location for cervical screening; all 
participants who attended there reported paying less than €40.  Therefore, as free 
cervical screening for all women is not considered cost-effective in Ireland 
(CervicalCheck, 2008), it is possible that if the young women in the present study 
were informed of the discounted health services available to them and crucially, of 
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the importance of cervical screening in the prevention of cervical cancer, the cost 
of screening may become a lesser concern (Irish Cancer Society, 2008; Ni Riain et 
al, 2003).  Additionally, the majority of participants in the present study stated 
that women under 25 should be screened; yet, the abovementioned barriers and 
the findings that only one-third of participants aged 20 and over have attended for 
cervical screening, suggests that if the young women in the present study were 
offered screening by their healthcare-provider, they would avail of it (Hennig and 
Knowles, 1990, in Irish Cervical Screening Programme, 2004c).  Finally, 
participants in the present study largely agreed that young girls should be 
vaccinated against HPV; however, their comments (see Appendix L) suggest that 
whilst they support the primary prevention of cervical cancer, they acknowledge 
that HPV-vaccination is not the panacea for cervical cancer, instead more 
education on the primary and secondary prevention of cervical cancer is required 
(Stark et al, 2008).  
 
5.3 Methodological Limitations of the Research 
A number of limitations occurred in relation to this research; shrewd readers may 
find more.  Firstly, as no information was known about the young women who 
declined to respond to the present study, the findings cannot be extrapolated to all 
young women attending a third-level institute (Barry et al, 2007), whilst the 
confinement of the present study’s sample to young third-level female students 
makes generalisations about the female population as a whole problematic 
(Philips et al, 2003).  Secondly, studies have demonstrated that sufficient 
knowledge about cervical cancer prevention and the uptake of preventative 
screening is positively associated with educational achievement, with the 
inference that such knowledge may be poorer in the wider population than in the 
third-level sample used in the present study (Philips et al, 2003; Gerend and 
Magloire, 2008; Sabates and Feinstein, 2006).  Thirdly, participants in the present 
study were not asked how many sexual partners they have had in the last year; as 
HPV is transient the likelihood of infection establishing persistency becomes 
more probable if the woman has had multiple partners in the last year (Winer et al, 
2003).  Fourthly, due to the small number of preinvasive cervical cancer cases 
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reported in the present study, statistical associations could not be ascertained 
between preinvasive cervical cancer screening results and the presence of the risk-
factors.  A further limitation in the present study, was that the third-level 
institute’s emailing system did not differentiate between male and female 
students; however, due to the stereotypically pink design of the present study’s 
internet survey, the depth of information required from respondents and the 
study’s inclusion criteria, the likelihood of males having participated in the 
present study was implausible.  
 
5.4 Summary 
This chapter discussed the research findings in relation to the aims of the present 
study.  The discussion showed a high prevalence of the sexual behaviour risk-
factors for contracting HPV among participants in the present study, which 
increased the likelihood of cervical screening attendance, but may have 
contributed to the high incidence of STIs.  Additionally, a high prevalence of the 
co-factors (smoking and long-term OCP use) that act in-conjunction with HPV to 
increase the risk of developing cervical cancer was also noted among participants 
(International Agency for Research on Cancer, 2005).  This chapter also referred 
to the high proportion of cervical screenings performed within the present study, 
on participants aged under 20 and within a year of sexual debut and concluded 
that this may have played a part in the high proportion of abnormal cervical 
screenings (one-third) reported.  Additionally, the discussion of participants’ 
abnormal results and the prevalence of the sexual  behaviour HPV risk-factors 
within the present study, suggested that some participants may be infected with 
HPV, while the lack of association between abnormal results and the presence of 
the co-factors, suggested that the effects the co-factors have may be more visible 
long-term.  The discussion of the key barriers to the prevention of cervical cancer 
implied that knowledge of and communication about preventing cervical cancer in 
the present study was not adequately addressed, prior to the initiation of cervical 
screening, within school-based sex education and with healthcare-providers; 
consequently, this may have exaggerated the barriers to cervical screening 
attendance.  Finally, as no consistent pattern emerged in the present study 
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regarding the initiation of cervical screening, the discussion concluded that firstly, 
healthcare-providers were uncertain about the best practice for screening women 
aged under 25 and secondly, healthcare-providers needed to pay more attention to 
the presence of the risk-factors, especially the sexual behaviour risk-factors, when 
initiating cervical screening, rather than depending on an age-standardised 




























6.1 Introduction  
This chapter draws a conclusion as to the present study and makes 
recommendations based on the findings and discussion.  
 
6.2 Conclusion 
The present study used a self-completion internet survey as outlined in Chapter 
Three, to examine the prevalence of the risk-factors for contracting HPV and 
developing cervical cancer, among 242 sexually active female students aged 18-
24 attending a third-level institute.  Consistent with the ISSHR’s findings (Layte 
et al, 2006), the present study demonstrated that the prevalence of the sexual 
behaviour risk-factors for contracting HPV, which tended to occur concurrently, 
appear to be increasing among young women; namely, being sexually active at a 
young age, having increasing numbers of sexual partners for females and their 
partners, and having an STI.  This also corresponds to research that HPV, the 
aetiological cause of cervical cancer, is the most commonly reported STI among 
young people in Ireland (Gilson and Mindel, 2001; Health Protection Surveillance 
Centre, 2008b).  Moreover, a high prevalence of the co-risk-factors, smoking and 
long-term OCP use, was also noted within the present study, which is again 
comparable to research (Layte et al, 2006). 
 
The present study also demonstrated that the presence of the sexual behaviour 
risk-factors tended to increase the likelihood of firstly, attending for cervical 
screening and secondly, receiving an abnormal cervical screening result; although 
less than one-third of participants in the present study had attended for screening, 
over one-third of screening results were abnormal, including one-tenth 
preinvasive cervical cancer.  Nevertheless, this high proportion of abnormal 
results may be accounted for by the abovementioned high prevalence of the sexual 
behaviour risk-factors and the findings from the present study that over one-half 
of participants attended for screening before the minimum recommended cervical 
screening age of 20, whilst over one-third of participants attended for screening 
within a year of sexual debut (European Commission, 2003, in Sasieni and 
Castanon, 2006; Deacon et al, 2000).  Furthermore, the present study also 
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demonstrated that healthcare-providers appeared to be inconsistent in their 
approach to screening young women, as some participants were screened before a 
HPV infection would have time to establish persistency (Kitchener et al, 2006), 
while other participants were refused cervical screening on the basis of their age, 
under 25.  
 
Finally, the present study also demonstrated that participants’ key barrier to the 
prevention of cervical cancer, appeared to be a low level of sufficient knowledge 
about the prevention of cervical cancer; this lack of knowledge was linked to a 
lack of communication and education from both healthcare-providers and school-
based sex education, about the transmission of HPV and the purpose and 
importance of cervical screening.  Consequently, the present study found that such 
insufficient education and communication tended to exasperate the personal 
(emotional) and practical (availability of screening) barriers to cervical screening 
attendance, and may have contributed to firstly, the high prevalence of the sexual 
behaviour risk-factors found within the present study and secondly, to the 
considerable proportion of participants who reported having an STI (one-tenth).  
 
6.3 Recommendations 
Several recommendations stem from the results of the present study and the 
consequent discussion of these findings. 
 
Firstly, greater education and communication about the importance and purpose 
of cervical screening and the risk-factors for developing cervical cancer, 
specifically the transmission of HPV, needs to be disseminated to adolescents and 
young people; this may lead to the adoption of preventative health behaviours, 
such as reducing possible risky sexual behaviours and may also alleviate the 
anxieties associated with cervical screening attendance (Sabates and Feinstein, 
2006; Fylan, 1998; Philips et al, 2003; Kahn et al, 2001). 
    
Secondly, as the present study showed, the prevalence of the risk-factors, 
specifically the sexual behaviour risk-factors for contracting HPV, appear to be 
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increasing among young women.  Therefore, rather than initiating cervical 
screening by reason of age-standardisation which may result in young women 
being refused screening irrespective of their risk, cervical screening guidelines 
should stipulate the initiation of screening from age 20 onwards based on the 
presence of the established risk-factors, as this is a more accurate determinant of 
the young woman’s necessity in attending for cervical screening (International 
Agency for Research on Cancer, 2003, 2005).  As such, these guidelines may 
firstly, reduce the high proportion of inaccurate cervical screenings reported in the 
present study, secondly, detect abnormalities that would otherwise not be detected 
until after age 25 and then possibly at an advanced CIN grade and thirdly, such 
guidelines may also encourage young women to become habitual about cervical 
screening (Sasieni and Castanon, 2006; Keegan et al, 2007).  Additionally, the 
sensitive personal information provided by participants in the present study, 
suggests that young women may be willing to provide such information for risk-
stratification to their healthcare-providers, making risk-based cervical screening 
feasible (Barry et al, 2007).  
 
 A final recommendation made by the present study, is that a long-term, in-depth 
study on the cervical screening attendance and results of young women in relation 
to the presence of the risk-factors is carried out; this will help determine if the 
current minimum age of 25 for free cervical screening with CervicalCheck should 
be lowered, in keeping with current research reporting a lower mean age for first 
sexual intercourse and increasing numbers of sexual partners and STIs, especially 
HPV (Layte et al, 2006; Sigurdsson and Sigvaldason, 2007; Gilson and Mindel, 
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